SECTION 1: BIOMARKERS
CONCEPTUAL SUMMARY
A biomarker is a measurable biological characteristic used to indicate normal or pathological processes or responses to therapy. In oncology, biomarkers are classified into two main categories:
- Prognostic biomarkers provide information about cancer outcomes independent of treatment. They predict the natural course of the disease — how aggressive it is, how likely it is to recur, or how long a patient may survive — regardless of the therapy received. Examples include
- Predictive biomarkers provide information about the likelihood of response or benefit from a specific treatment. They help select the right therapy for the right patient. Examples include
- EGFR mutations in lung cancer (predicting response to EGFR TKIs),
- BRAF V600E mutations in melanoma (predicting response to BRAF inhibitors), and
- AR-V7 in prostate cancer (predicting reduced response to enzalutamide).
A biomarker can be both prognostic and predictive if it independently predicts cancer outcomes AND predicts response to a specific therapy. Examples include activating EGFR mutations in lung cancer and PIK3CA mutations in HER2-positive breast cancer.
Key Diagnostic Concepts:
- Next-generation sequencing (NGS) can be hotspot (targeted regions only), whole exome (all coding regions), or whole genome (entire genome). Hotspot tests cover only specified regions and may miss mutations outside those areas.
- Cell-free DNA (cfDNA) plasma-based assays detect circulating tumor DNA shed from tumor cells into the bloodstream and are most useful in patients with high disease volume and multiple sites of metastatic disease.
- Brain metastases may shed limited cfDNA across the blood-brain barrier, but other extracranial disease sites compensate.
- MSI-High and TMB-High are pan-tumor biomarkers that predict response to pembrolizumab. Only pembrolizumab (not nivolumab or atezolizumab) is FDA-approved for MSI-high and TMB-high non-colorectal solid tumors.
- Companion Diagnostic Tests are FDA-approved tests required to be used with a specific drug. Examples include
PRACTICE QUESTIONS — BIOMARKERS
BT is a 62-year-old man with metastatic, castration-resistant prostate cancer. A tumor biopsy reveals a splice variant in the androgen receptor known as AR-V7. Men with prostate cancer treated with enzalutamide had lower PSA response rates and overall survival if their tumors harbored the AR-V7 alteration. It is not known whether patients with AR-V7 alterations have poorer overall outcomes than patients without the alteration, regardless of therapy. AR-V7 would be classified as which type of biomarker?
A. Prognostic only
B. Predictive only
C. Both prognostic and predictive
D. Neither prognostic nor predictive
Explanation: AR-V7 is associated with a lower response to enzalutamide, which classifies it as a predictive biomarker because it provides information about response to a specific therapy. Insufficient information is available to determine whether AR-V7 is prognostic in nature; this requires treatment-independent cancer outcome analysis. Since no data is provided regarding outcomes regardless of therapy, it cannot be classified as prognostic.
[/expand]BF is a 41-year-old male with newly diagnosed glioblastoma being screened for a clinical trial of an anti-EGFR monoclonal antibody conjugate. The institution's in-house NGS test assesses the intracellular portion of the EGFR protein kinase region. Is this test appropriate for analyzing BF's tumor?
A. Yes, this is a hotspot NGS test that will cover the area of interest in the EGFR gene
B. Yes, this is a whole exome test that will cover the area of interest in the EGFR gene
C. No, this is a hotspot NGS test that will not cover the area of interest in the EGFR gene
D. No, this is a whole-genome test that will not cover the EGFR gene with enough reads
Explanation: The NGS test only covers the intracellular portion of the EGFR gene, making it a hotspot test. For glioblastoma, the most common EGFR mutations — including the EGFR vIII alteration resulting from deletion of exons 2–7 — occur in the extracellular portion of the EGFR gene. If only the intracellular region is sequenced, this assay will miss the clinically relevant mutations. This type of hotspot test covering the intracellular kinase domain would be appropriate for a lung cancer patient where the majority of EGFR alterations occur in that region.
[/expand]BF is a 41-year-old male with newly diagnosed lung cancer being screened for a clinical trial of an anti-EGFR TKI. The institution's in-house NGS test assesses the intracellular portion of the EGFR protein kinase region. Is this test appropriate for analyzing BF's tumor?
A. Yes, this is a hotspot NGS test that will cover the area of interest in the EGFR gene
B. Yes, this is a whole exome test that will cover the area of interest in the EGFR gene
C. No, this is a hotspot NGS test that will not cover the area of interest in the EGFR gene
D. No, this is a whole genome test that will not cover the EGFR gene with enough reads
Explanation: For lung cancer patients, the majority of clinically relevant EGFR alterations (such as the L858R mutation and exon 19 deletions) occur in the intracellular protein kinase domain — exactly the region covered by this hotspot NGS test. Therefore, this assay is appropriate for a lung cancer patient, unlike for a glioblastoma patient where the key mutations are extracellular.
[/expand]VB is a 48-year-old female with NSCLC with EGFR L858R mutation and metastatic disease in the liver and adrenal gland. She was initially treated with erlotinib for 8 months but now has progression, including new brain and pelvic bone lesions. The team would like to assess for resistance mutations. Is VB an appropriate candidate for a cfDNA plasma-based assay?
A. No, because she has advanced disease that has progressed on first-line therapy
B. No, because cfDNA assays are not yet recommended in standard clinical practice
C. Yes, because she is progressing on current therapy and has several sites of metastatic disease
D. Yes, because she has a new lesion in the brain
Explanation: VB is a good candidate for cfDNA plasma-based testing because she has a high volume of disease that is currently progressing. Though she has a brain lesion that may not shed cfDNA enough across the blood-brain barrier, she has multiple other sites of progressive extracranial disease. Several commercial cfDNA assays are available in clinical practice, and in patients with advanced disease and low albumin levels, sensitivity is approximately 80%.
[/expand]TL is a 67-year-old female with metastatic lung adenocarcinoma with EGFR L858R mutation and spine metastasis. She was treated with osimertinib for 16 months but now has lung progression and a new brain lesion. The team would like to assess for resistance mutations. Is TL an appropriate candidate for a cfDNA plasma-based assay?
A. No, because she has advanced disease that has progressed on first-line therapy
B. No, because cfDNA assays are not yet recommended in standard clinical practice
C. Yes, because she is progressing on current therapy and has several sites of metastatic disease
D. Yes, because she has a new lesion in the brain
Explanation: TL is a good candidate for cfDNA plasma-based testing because she has high-volume disease currently progressing on osimertinib. Though she has a brain lesion that may not shed enough cfDNA across the blood-brain barrier, she has other sites of progressive disease outside the brain. Several commercial cfDNA assays are available in clinical practice for patients with advanced disease.
[/expand]RM is a 55-year-old female with metastatic endometrioid adenocarcinoma of the endometrium who was initially treated with carboplatin and paclitaxel, followed by a phase I PI3K inhibitor trial. A new biopsy is found to be MSI-high. Which treatment option is most appropriate for RM at this time?
A. Nivolumab
B. Nivolumab and ipilimumab
C. Pembrolizumab
D. Atezolizumab
Explanation: Currently, only pembrolizumab is indicated for MSI-high non-colorectal solid tumors. Nivolumab with or without ipilimumab is an option for patients with MSI-high colorectal cancers following prior therapy with fluoropyrimidine, oxaliplatin, and irinotecan — not for non-colorectal tumors. Atezolizumab is currently not approved for any MSI-high tumors.
[/expand]RM is a 55-year-old female with metastatic endometrioid adenocarcinoma of the endometrium who was initially treated with carboplatin and paclitaxel followed by a phase I PI3K inhibitor. A new biopsy is found to be TMB-high. Which treatment option is most appropriate for RM at this time?
A. Nivolumab
B. Nivolumab and ipilimumab
C. Pembrolizumab
D. Atezolizumab
Explanation: Pembrolizumab is FDA-approved for unresectable or metastatic TMB-high (≥ 10 mutations/megabase) solid tumors that have progressed following prior treatment and have no satisfactory alternative options. This approval is tumor-agnostic. Nivolumab with or without ipilimumab and atezolizumab do not have this specific TMB-high indication.
[/expand]VD is a 45-year-old male with metastatic colorectal cancer initially treated with FOLFOX followed by cetuximab + FOLFIRI. He developed a new lung lesion. NGS testing found the tumor to be MSI-high. Which treatment option is most appropriate for VD at this time?
A. Atezolizumab
B. Ipilimumab
C. Nivolumab and ipilimumab
D. Ramucirumab
Explanation: For patients with MSI-high colorectal cancer following prior therapy with fluoropyrimidine, oxaliplatin, and irinotecan, nivolumab with or without ipilimumab is an approved option. VD has received FOLFOX (fluoropyrimidine + oxaliplatin) and FOLFIRI (fluoropyrimidine + irinotecan) — fulfilling the prior therapy requirement. Atezolizumab is not approved for MSI-high tumors. Ramucirumab is a VEGFR-2 inhibitor with no MSI-high indication.
[/expand]OB is a 38-year-old male with metastatic soft tissue sarcoma that has progressed on 3 prior lines of therapy. A cfDNA test reveals a TPM3-NTRK1 fusion. The team is considering larotrectinib. Is larotrectinib appropriate for this patient at this time?
A. Yes, larotrectinib is appropriate
B. No, larotrectinib is only approved for pediatric sarcomas
C. No, larotrectinib is only approved for activating NTRK1 missense mutations
D. No, because this was a cfDNA rather than tumor-based NGS test
Explanation: Larotrectinib is approved for use in both pediatric and adult patients with NTRK1-3 gene fusions, consistent with this TPM3-NTRK1 fusion. This patient has an activating NTRK1 fusion in a metastatic tumor that has progressed on three prior lines of therapy. Clinically relevant missense NTRK1-3 mutations are typically described in the acquired resistance setting. Both cfDNA and tumor-based NGS assays are acceptable for identifying NTRK1-3 fusions.
[/expand]MS is a 38-year-old woman with metastatic cervical cancer who has received 2 prior lines of chemotherapy. Her original tissue has a PD-L1 Combined Positive Score (CPS) of 80 on the PD-L1 22C3 PharmDx assay. Which is the best choice for MS at this time?
A. Nivolumab
B. Atezolizumab C.
C. Pembrolizumab
D. Avelumab
Explanation: The PD-L1 22C3 PharmDx assay is the companion diagnostic for pembrolizumab. Nivolumab uses the IHC 28-8 assay, and atezolizumab uses the PD-L1 SP142 assay. Pembrolizumab is FDA-approved as a single agent in patients with metastatic cervical cancer following disease progression on or after chemotherapy for tumors that express PD-L1 CPS ≥ 1. This patient's CPS score was 80, well above the threshold.
[/expand]MN is a 45-year-old female with metastatic gastric cancer (HER2 +3 by IHC) initially treated with cisplatin + 5-FU + trastuzumab followed by ramucirumab. She developed a new liver lesion. PDL-1 testing shows CPS = 3. Which treatment option is most appropriate at this time?
A. Ipilimumab
B. Pembrolizumab
C. Atezolizumab
D. Nivolumab
LC is a 49-year-old man with astrocytoma, IDH1 R132H mutated. Additional testing shows homozygous CDKN2A loss. CDKN2A homozygous loss is associated with significantly shorter PFS and OS in IDH-mutated gliomas. CDK4/6 inhibitors assessed in trials for CDKN2A loss showed no notable clinical benefit. CDKN2A homozygosity loss would be classified as what type of biomarker?
A. Prognostic only
B. Predictive only
C. Both prognostic and predictive
D. Neither prognostic nor predictive
Explanation: CDKN2A provides information about cancer outcomes and is specifically associated with poor PFS and OS, making it a prognostic biomarker. It reflects underlying cancer biology and upgrades the WHO grade to 4. CDKN2A loss has NOT been associated with response to CDK4/6 inhibitors and therefore would not be considered a predictive biomarker. Predictive biomarkers provide information regarding response to specific treatments.
[/expand]PIK3CA mutations in patients with HER2-positive breast cancer and NOTCH1 mutations in CLL patients are examples of which type of biomarker?
A. Prognostic only
B. Predictive only
C. Both prognostic and predictive
D. Neither prognostic nor predictive
Explanation: PIK3CA mutations in HER2-positive breast cancer predict resistance to HER2-targeted therapy (predictive) and are also associated with worse outcomes (prognostic). NOTCH1 mutations in CLL are associated with poorer OS and faster disease progression (prognostic) and predict reduced response to certain therapies (predictive). Biomarkers can be both prognostic and predictive when they independently provide information about cancer outcomes AND predict response to a specific treatment.
[/expand]TP53 mutations in CLL and FLT3 internal tandem duplication (ITD) in AML are examples of which type of biomarker?
A. Prognostic only
B. Predictive only
C. Both prognostic and predictive
D. Neither prognostic nor predictive
The sources explicitly state that while many biomarkers fall into one category, certain markers like TP53 and FLT3 ITD serve both functions simultaneously. TP53 mutations in CLL: These are classified as prognostic because they are associated with the "worst outcomes," including short treatment-free intervals and short median survival. They are also predictive because they indicate a lack of response to standard chemoimmunotherapy and help direct the use of specific targeted agents like venetoclax [/expand]
Activating EGFR mutations in lung cancer and BRAF V600 mutations in melanoma are examples of which type of biomarker?
A. Prognostic only
B. Predictive only
C. Both prognostic and predictive
D. Neither prognostic nor predictive
The sources categorize biomarkers into specific groups based on their clinical utility:
- Predictive Biomarkers: These provide information regarding the likelihood of response to a specific treatment. The sources explicitly list both of your examples under the "Examples of predictive biomarkers" section:
- Activating EGFR mutations in lung cancer: These are associated with an increased response to EGFR-inhibitors such as erlotinib, gefitinib, afatinib, and osimertinib.
- BRAF V600 mutations in melanoma: These are associated with a response to the combination of BRAF and MEK inhibitors.
In contrast, prognostic biomarkers (like PIK3CA in HER2-positive breast cancer or NOTCH1 in CLL) provide information about cancer outcomes independent of the treatment received. While some markers, such as TP53 in CLL or FLT3 ITD in AML, are identified as being both prognostic and predictive, activating EGFR and BRAF mutations are specifically highlighted in the sources for their predictive value in directing targeted therapy.
[/expand]FG is a 65-year-old man with epithelioid glioblastoma, IDH-wildtype, WHO grade 4. After gross total resection, NGS showed a BRAF V600E mutation. He received concurrent radiation and temozolomide followed by 6 cycles of temozolomide maintenance. His 3-month follow-up MRI showed recurrence. The neuro-oncology team is asking about dabrafenib and trametinib. Which of the following is true about this drug combination?
A. It is FDA approved for this scenario
B. It can be obtained off-label for this scenario
C. It has not been proven effective in high-grade gliomas like glioblastoma
D. Dabrafenib and trametinib showed benefit in low-grade gliomas but not high-grade gliomas
Explanation: The combination of dabrafenib and trametinib is FDA-approved for adults and pediatric patients > 6 years old with unresectable or metastatic solid tumors with the BRAF V600E mutation who have no satisfactory alternative treatment options. This approval included data from the ROAR phase 2 basket trial, which included a glioblastoma cohort with an ORR of 33% including 3 complete responses and 12 partial responses.
[/expand]BM is a 45-year-old man with metastatic colorectal cancer who received FOLFOX then bevacizumab + FOLFIRI. New lesions were found in lung and bone. His SCr = 1.3, ALT = 70, Bil = 0.9, Alb = 2.7. A KRAS genetic test is ordered as the patient is planned to receive cetuximab + fluorouracil as 3rd line. Is BM an appropriate candidate for a cfDNA plasma-based assay?
A. No, as BM had CRC which is associated with decreased sensitivity to cfDNA
B. Yes, as BM had many metastatic sites and received 2 lines of treatment
C. Yes, as KRAS genetic testing cannot be done by tumor genetic testing
D. No, as low albumin level is associated with decreased sensitivity to cfDNA testing
Explanation: BM has multiple sites of metastatic disease (lung and bone) and has progressed on 2 prior lines of therapy — both indicators of high disease burden making him a good candidate for cfDNA plasma-based testing. While low albumin may be associated with decreased cfDNA sensitivity, sensitivity remains approximately 80% in patients with advanced disease. KRAS testing CAN be done by tumor-based NGS. CRC is not specifically associated with decreased cfDNA sensitivity.
[/expand]Which one of the following is an approved companion diagnostic test for vemurafenib use in melanoma?
A. Cobas EGFR Mutation test v2 (PCR)
B. Cobas 4800 BRAF V600 Mutation test (PCR)
C. Vysis CLL FISH Probe Kit
D. VYSIS ALK Break Apart FISH Probe Kit
Explanation: The Cobas 4800 BRAF V600 Mutation test is the FDA-approved companion diagnostic for vemurafenib in melanoma. It detects the BRAF V600E mutation in melanoma tissue. The Cobas EGFR Mutation test is the companion diagnostic for certain EGFR-targeted therapies in lung cancer. The Vysis CLL FISH Probe Kit is used for chromosomal analysis in CLL. The VYSIS ALK Break Apart FISH Probe Kit detects ALK rearrangements in lung cancer.
[/expand]Which one of the following is an approved companion diagnostic test for alpelisib use in HR+/HER2− metastatic breast cancer?
A. VENTANA ALK (D5F3) CDx Assay (IHC)
B. Vysis CLL FISH Probe Kit
C. THxID BRAF Kit (PCR)
D. therascreen PIK3CA RGQ PCR Kit
Explanation: The therascreen PIK3CA RGQ PCR Kit is the FDA-approved companion diagnostic for alpelisib (Piqray), a PI3K inhibitor used in HR+/HER2− metastatic breast cancer with a PIK3CA mutation after endocrine therapy. The VENTANA ALK assay is for ALK-positive NSCLC. The Vysis CLL FISH Probe Kit is used in CLL. The THxID BRAF Kit detects BRAF V600E/K mutations.
[/expand]SECTION 2: PHARMACOECONOMICS
CONCEPTUAL SUMMARY
- Pharmacoeconomics evaluates the costs and consequences of pharmaceutical products and services. Understanding the types of costs and analyses is essential for formulary management and health system decision-making.
- Types of Costs:
- Fixed costs do not change with volume of services (e.g., cost of lights, equipment, building).
- Variable costs change with volume (e.g., cost of medications, supplies).
- Direct medical costs are directly related to the medical service (e.g., drugs, hospitalizations).
- Direct non-medical costs are non-healthcare costs directly related to illness (e.g., transportation to clinic).
- Indirect costs result from loss of productivity or employment due to illness (e.g., lost wages).
- Intangible costs represent pain, suffering, or reduced quality of life.
- Incremental costs are additional costs resulting from adding a new intervention. Opportunity costs represent the value of the next best alternative foregone when a resource is used.
- Types of Analyses:
- Cost-minimization analysis (CMA): Used when two treatments are assumed equal in efficacy; only costs are compared.
- Cost-effectiveness analysis (CEA): Compares costs AND a single clinical outcome. Cannot compare programs with different outcomes.
- Cost-utility analysis (CUA): Compares costs AND patient quality-of-life outcomes (QALYs). More complex and expensive.
- Cost-benefit analysis (CBA): All outcomes are converted to monetary values. Can compare programs with completely different outcomes. Best used when comparing unlike interventions.
- Cost-of-illness (COI): Measures the total economic burden of a disease; does not assess the efficiency of resource use.
- Cost-effectiveness = Cost ÷ Effect. The drug with the lowest ratio provides the most value per unit of outcome.
PRACTICE QUESTIONS — PHARMACOECONOMICS
Your institution wants to evaluate the addition of coagulation factor Xa (recombinant), inactivated-zhzo to the formulary for reversal of direct oral anticoagulants. Which best describes the type of cost this medication would have?
A. Fixed medical
B. Variable medical
C. Indirect
D. Incremental
Explanation: The cost of a medication is a variable medical cost because it changes with the volume of patients treated. The cost of the lights in the clean room would be a fixed medical cost. Time resulting in loss of work for a patient would be an indirect cost. The additional use of blood products after administration would be an incremental cost.
[/expand]Your institution wants to use pharmacoeconomic data to evaluate the impact of coagulation factor Xa (recombinant), inactivated-zhzo on neurologic disability and cost compared with prothrombin complex concentrate. Which analysis would be best to find in the literature?
A. Cost-benefit
B. Cost-effectiveness
C. Cost-minimization
D. Cost-utility
Explanation: Given the need to consider both efficacy (neurologic disability) and cost, a cost-effectiveness analysis is most appropriate. A cost-benefit analysis would be used if purely interested in a monetary outcome. A cost-minimization analysis only evaluates the difference in costs and assumes equal efficacy. A cost-utility analysis includes the patient quality-of-life perspective, which was not the focus of this evaluation.
[/expand]Which best describes the type of cost of the additional use of blood products after administration of coagulation factor Xa (recombinant), inactivated-zhzo?
A. Fixed medical
B. Variable medical
C. Indirect
D. Incremental
Explanation: Incremental costs represent the additional costs resulting from adding a new intervention. The additional blood products used after administration of the new drug represent costs incurred on top of standard care and are therefore incremental.
[/expand]J.R. is a 30-year-old woman admitted to the surgical ICU after a motor vehicle accident. Which best exemplifies an indirect cost from her perspective?
A. Loss of wages from her occupation as an engineer
B. Effects of post-traumatic stress disorder from her accident
C. Fentanyl administered to manage her pain
D. Cost of the ambulance that transported her to the hospital
Explanation: Indirect costs occur from loss of employment or productivity as a result of illness or injury. Effects from PTSD would be considered an intangible cost. Costs from fentanyl and transportation are direct costs (direct medical and direct non-medical, respectively).
[/expand]Which drug is most suitable to be added to the formulary based on cost-effectiveness?
[expand] Answer: Drug CExplanation: Cost-effectiveness is calculated as Cost ÷ Effect (cost per mm Hg reduction):
- Drug A: 200 ÷ 5 = $40.00 per mm Hg
- Drug B: 150 ÷ 8 = $18.75 per mm Hg Drug
- C: 250 ÷ 18 = $13.88 per mm Hg Drug
- D: 300 ÷ 15 = $20.00 per mm Hg
Drug C has the lowest cost per mm Hg of BP reduction ($13.88), making it the most cost-effective option and the best choice for formulary addition.
[/expand]A wealthy donor left your institution $10 million to establish a clinic for one of three disorders: depression, obesity, and smoking. You want to conduct a pharmacoeconomic study to inform the decision. Which type of analysis would be best?
A. Cost-benefit
B. Cost-effectiveness
C. Cost-of-illness
D. Cost-utility
Explanation: Because three completely different outcomes are being evaluated, cost-effectiveness cannot be used — it can only compare programs with the same unit of outcome. Cost-of-illness does not provide information on effective or efficient use of resources. Cost-utility studies are complicated and expensive, and an alternative should be used when possible. Cost-benefit analysis can compare different types of outcomes by converting all outcomes to monetary values, making it the most appropriate choice when comparing unlike interventions.
[/expand]The local health system is conducting a cost-benefit analysis on opening a dialysis center. The nearest center is currently 75 miles away. Which best depicts an opportunity cost to the health system?
A. Opening of a new cancer center
B. Equipment for the dialysis center
C. Decreased transportation costs
D. Work hours gained
Explanation: Opportunity costs represent the value of the next best alternative that must be foregone when a resource is committed to one use. By using the resources to build the dialysis center, the health system foregoes building a cancer center — that is the opportunity cost. Equipment for the dialysis center is part of the actual cost. Decreasing transportation costs is a reduction in direct non-medical costs. Work hours gained is an economic outcome, not an opportunity cost.
[/expand]You have designed a new survey instrument to directly measure satisfaction with health and are starting a study in a general population of older adults to identify norms. Which category of assessment best categorizes your research?
A. Economic modeling
B. Outcomes research
C. Patient-reported outcomes
D. Pharmacoeconomic analysis
Explanation: Satisfaction surveys are completed directly by the patient without interpretation by a clinician, so this project is categorized as patient-reported outcomes research per the FDA definition. No mention of pharmaceuticals was made, so it is not a pharmacoeconomic analysis. Because the project involves a survey completed by individuals, modeling is not being done. Outcomes research involves measuring changes in patient outcomes, but this project is measuring the level of satisfaction rather than changes.
[/expand]A national group is conducting a study on the change in cost of illness for a major disease after the first biological specialty drug had been on the market for 1 year. Which type of outcome study would be most applicable to the data?
A. General outcomes research study
B. Cost-benefit analysis
C. Cost-utility analysis
D. Cost-effectiveness with patient-reported outcomes
Explanation: Cost-of-illness analyses normally include direct medical costs and indirect costs expressed in monetary units. Health-related quality of life and utilities cannot be determined from these data points, making cost-utility and cost-effectiveness with patient-reported outcomes incorrect. Because the data are most easily collected as dollars of cost and outcome, a cost-benefit analysis can be performed.
[/expand]SECTION 3: DRUG INFORMATION AND REGULATORY AFFAIRS
CONCEPTUAL SUMMARY
Drug Information Resources:
- Primary resources are original research studies.
- Secondary resources index primary literature (e.g., PubMed, Embase).
- Tertiary resources are textbooks and compendia (e.g., Micromedex, Martindale, USP-NF, Up-To-Date).
- Martindale covers drugs and related substances of clinical interest worldwide.
- USP 797 covers sterile compounding standards.
- The FDA website provides information on newly approved drugs and vaccines.
- Guidelines.gov, Trip, NIH, and Up-to-Date provide recently published clinical guidelines.
Adverse Event Reporting:
- MedWatch (FDA): For reporting serious adverse drug reactions, product quality problems, product use errors, and therapeutic failures.
- Mandatory for manufacturers; voluntary for healthcare professionals and consumers. Fatal medical device adverse events are reported to MedWatch.
- ISMP:
- Receives reports of medication errors through the National Medication Error Reporting Program. Confidential and voluntary. After a report, ISMP will contact the FDA and manufacturer.
- Joint Commission (TJC):
- Accredited organizations must report sentinel events. A sentinel event is an unexpected occurrence involving death or serious physical or psychological injury (e.g., wrong-site surgery, retained surgical instruments).
- Root Cause Analysis (RCA) is performed after a sentinel event.
- Failure Mode Effect Analysis (FMEA) is a proactive tool to anticipate and prevent potential failures. Naranjo Scale: Assesses the probability that an adverse event is caused by a specific drug. It quantifies causality — not severity or reversibility.
Drug Recalls:
- Class I: Reasonable probability of serious adverse health consequences or death.
- Class II: May cause temporary adverse health consequences or a remote probability of serious consequences.
- Class III: Unlikely to cause adverse health consequences.
HIPAA:
- Protects individually identifiable health information.
- Enforced by the DHHS Office of Civil Rights.
- Medical students are permitted to access patient files when part of the care team.
- Voicemail messages are permitted but must limit protected information.
- Email of PHI is acceptable if the patient acknowledges the risk in writing.
- Patient files must be kept in secure locations.
IRB:
- Reviews human subjects research. Exempt review: minimal risk research categories (anonymous surveys, educational research, secondary analysis of de-identified specimens). Expedited review: no more than minimal risk (non-invasive diagnostic devices, blood sample collection). Full review: more than minimal risk. Informed consent must contain: research description, risks, benefits, alternatives, confidentiality, compensation, contact information, and voluntary participation. Assent is obtained from minors aged 7–17; a parent/guardian provides formal consent.
Ethics:
- Beneficence: acting in the best interest of the patient.
- Non-maleficence: avoiding harm.
- Justice: fair distribution of resources.
- Autonomy: respecting patient decisions.
- Just culture: non-punitive environment encouraging error reporting.
Quality Indicators:
- Structure: resources and organizational features (e.g., staff-to-patient ratio).
- Process: actions taken in care delivery (e.g., appropriate timing and dosage).
- Outcome: results of care (e.g., TTR, HbA1c levels).
PRACTICE QUESTIONS — DRUG INFORMATION AND REGULATORY AFFAIRS
A device pump error (it works automatically) results in a dose error. To whom should this be reported?
A. FDA (MedWatch)
B. ISMP
Explanation: Medical device adverse events — including infusion pump errors — are reported to the FDA through MedWatch. The FDA's Medical Device Reporting (MDR) program monitors device performance and detects potential device-related safety issues. ISMP handles medication error reports, not medical device malfunctions. Fatal medical device adverse events are also reported to MedWatch.
[/expand]An infusion pump error leads to patient death. To whom should the death be reported?
A. FDA (MedWatch)
B. The Joint Commission (TJC)
Explanation: Fatal medical device adverse events must be reported to the FDA through MedWatch. Device user facilities (hospitals and nursing homes) are required to report device-related deaths to the FDA and to the device manufacturer. While TJC requires reporting of sentinel events for accredited organizations, the regulatory reporting for fatal device-related events goes to the FDA.
[/expand]A medication error (error in dose) occurs. To whom should it be reported?
A. Joint Commission
B. ISMP
Explanation: ISMP operates the National Medication Error Reporting Program, which receives confidential voluntary reports of medication errors including wrong drug, wrong dose, wrong patient, wrong route, and calculation or preparation errors. The Joint Commission requires reporting of sentinel events from accredited organizations, but standard medication dose errors without serious patient harm are directed to ISMP rather than TJC.
[/expand]A pharmacotherapist wants to research the causality of certain drugs and define adverse events using FDA data. A colleague says FDA data is not reliable. Which statement is correct?
A. FDA isn't reliable; not all reports reach the FDA and he should depend on other extra resources
B. FDA is a reliable resource to depend on
Explanation: The FDA is one of the main drug information resources about adverse events of drugs. While voluntary reporting has limitations, the FDA database remains a primary and reliable resource for pharmacovigilance research. Researchers should be aware of limitations but can use FDA data as a reliable primary source.
[/expand]Assessment of adverse event causality should use which tool?
A. Naranjo scale
B. FEMA
Explanation: The Naranjo scale is the standard tool used to assess the probability that an adverse event is caused by a specific drug. It assigns a score based on questions about prior reports, drug levels, timing, and dechallenge/rechallenge. FEMA (Failure Mode Effect Analysis) is a proactive safety tool used to prevent errors before they occur, not for causality assessment.
[/expand]The Adverse Event score of 10 on the Naranjo scale was calculated for elevated transaminase enzyme after high-dose etoposide. The main target of the Naranjo scale is?
A. Probability that the adverse event is secondary to etoposide
B. Quantify the severity
C. Determine if the doses are related
D. Predict if adverse events are reversible when etoposide is stopped
Explanation: The Naranjo scale is designed to assess the probability of a causal relationship between a drug and an adverse event. A score of 10 indicates a definite causal relationship. It does NOT quantify severity, determine dose-relatedness, or predict reversibility. It is strictly a causality assessment tool.
[/expand]After a sentinel event, what is the appropriate first step?
A. Root cause analysis
B. Open discussion
Explanation: After a sentinel event, a Root Cause Analysis (RCA) is performed to identify the underlying systems-based causes and to develop corrective action plans to prevent recurrence. An open discussion alone is insufficient and does not meet accreditation requirements.
[/expand]FDA MedWatch data has limitations. Which is an accurate description of its limitations?
A. Reliable and can be used directly
B. Unreliable as there are many limitations concerning it (the healthcare team are not required to prove causality before reporting)
Explanation: MedWatch data has well-recognized limitations. Reporting is voluntary for healthcare professionals, so underreporting is common. Reporters are not required to prove causality before submitting — they only need to suspect a drug-event relationship. This means reports may include coincidental events unrelated to the drug. Despite these limitations, MedWatch remains a valuable pharmacovigilance tool when its limitations are acknowledged.
[/expand]A patient has tried all FDA-approved drugs without improvement. There is another drug with limited clinical trial data that is still not approved. What is the appropriate course of action?
A. Call the manufacturer to order the drug as an emergency
B. Get P&T committee approval
C. Get IRB approval
D. Wait until the drug is approved and order
Explanation: For patients who have exhausted all approved options, expanded access (compassionate use) allows access to investigational drugs. The treating physician contacts the manufacturer directly to request the drug under an expanded access/compassionate use protocol through an IND application submitted to the FDA. The initial step is contacting the manufacturer directly to initiate the expanded access request.
[/expand]What does HIPAA protect against?
A. The disclosure of health information without patient permission
B. Health information that is held or electronically transmitted
C. Both A and B
D. None of the above
Explanation: HIPAA has two key components. The Privacy Rule establishes national standards regulating the use and disclosure of individually identifiable health information without patient permission. The Security Rule sets national regulations protecting health information that is held or electronically transmitted. Both components together define the full scope of HIPAA protections.
[/expand]A patient with nonvalvular atrial fibrillation prescribed rivaroxaban is later started on rifampin, which increases rivaroxaban metabolism through CYP3A4 and P-glycoprotein induction, causing subtherapeutic rivaroxaban levels and a subsequent stroke. Which best describes this interaction?
A. Side effect
B. Adverse drug reaction (ADR)
C. Preventable adverse drug event (ADE)
D. ADE
Explanation: A preventable ADE is a medication error that reaches the patient and causes harm because of a breach of standard professional behavior or practice. The rifampin-rivaroxaban interaction is a known, documented drug interaction described in the prescribing information. Prescribing rifampin to a patient on rivaroxaban without adjusting therapy represents a medication error, and the stroke is the resultant harm. While it is also technically an ADR, a preventable ADE most precisely describes this case.
[/expand]What is the in-process indicator for an anticoagulation clinic?
A. Time in Therapeutic Range (TTR)
B. Providing evidence-based resources for appropriate warfarin dosage
C. Staff-to-patient ratio
Explanation: A process indicator measures whether the correct actions and procedures are being followed during care delivery. TTR is an outcome indicator. Staff-to-patient ratio is a structure indicator.
[/expand]What is the structure indicator for an anticoagulation clinic?
A. Time in Therapeutic Range (TTR)
B. Providing evidence-based resources for appropriate warfarin dosage
C. Staff-to-patient ratio
Explanation: Structure indicators measure the resources, organizational features, and infrastructure of a healthcare setting. Staff-to-patient ratio reflects the organizational capacity and resource availability. TTR is an outcome indicator. Providing evidence-based resources is a process indicator.
[/expand]What is the outcome indicator for an anticoagulation clinic?
A. Time in Therapeutic Range (TTR)
B. Providing evidence-based resources for appropriate warfarin dosage
C. Staff-to-patient ratio
Explanation: Outcome indicators measure the results of care delivered to patients. TTR directly reflects the clinical result of anticoagulation management — how well the patient's INR is controlled within the therapeutic range.
[/expand]Studying the appropriate time for the next visit in an anticoagulation clinic to check INR is which type of indicator?
A. Structure indicator
B. In-process indicator
C. Outcome indicator
Explanation: Determining the appropriate timing of INR monitoring visits is an in-process indicator because it measures whether the correct processes and procedures are being followed during care delivery.
[/expand]What is the outcome indicator for the use of warfarin in atrial fibrillation?
A. Adherence to guidelines
B. Percent of specialists in a healthcare facility
C. Percent of INR TTR (Time in Therapeutic Range)
Explanation: Outcome indicators measure the results of care. TTR reflects how well a patient's anticoagulation is managed and directly correlates with thromboembolic and bleeding outcomes. Adherence to guidelines is a process indicator. The percent of specialists is a structure indicator.
[/expand]A pharmacist calls a patient to inform him that his medications arrived, but he did not answer. What should the pharmacist do according to HIPAA?
A. Leave a voicemail freely mentioning private information
B. Leave a voicemail but limit the private information disclosed
C. HIPAA does not allow any voicemail through the answering machine
Explanation: HIPAA permits leaving voicemail messages for patients but requires that the amount of protected health information disclosed be limited. The pharmacist may leave a message confirming that medications are available and requesting a callback, but should not include detailed medication names or health conditions. HIPAA does not prohibit voicemail altogether.
[/expand]A medical student wants to access a patient's file. What does HIPAA say about this?
A. HIPAA privacy rule prohibits medical students' access to patient files
B. HIPAA permits medical students to get access to patient files
Explanation: HIPAA permits medical students, residents, and other healthcare trainees to access patient health information when they are part of the patient's treatment team. This falls under the treatment exception to HIPAA's privacy rules.
[/expand]Which act allows patients to use investigational drugs?
A. Obama Act
B. Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina (Right to Try Act)
Explanation: The Right to Try Act (2018) allows patients with life-threatening conditions who have exhausted approved treatment options to access certain investigational drugs that have completed Phase I clinical trials but have not yet received FDA approval, without going through the FDA's expanded access program.
[/expand]In expanded access drug use, the patient:
A. Must sign consent
B. No need for consent
Explanation: Patients participating in expanded access (compassionate use) protocols must provide informed consent before receiving the investigational drug. Informed consent is a fundamental ethical and regulatory requirement in all scenarios where a patient is exposed to an investigational or unapproved treatment.
[/expand]A non-punitive environment in reporting errors is best described as:
A. Just culture
B. Justice
C. Beneficence
D. Autonomy
Explanation: Just culture creates a non-punitive environment encouraging staff to report errors, near-misses, and unsafe conditions without fear of blame or punishment, while still holding individuals accountable for reckless behavior. It focuses on improving systems rather than punishing individuals for honest mistakes.
[/expand]Your parents bought you stock in a drug company when you were accepted into pharmacy school. The stock value exceeds $20,000. This company has just marketed a new drug, and as clinical manager, it is your responsibility to present the drug to the P&T committee for possible formulary addition.
Do you have any ethical or legal responsibility to disclose your stock holdings?
A. Yes, because there is a CMS requirement to disclose any material holdings exceeding $10,000
B. No, because the stock purchase was made by someone else without your knowledge
C. No, because you are not a voting member of the P&T committee
D. Yes, because the stock holding could be perceived as a conflict of interest
Answer: D. Yes, because the stock holding could be perceived as a conflict of interest
Explanation: The stock holding must be disclosed to the P&T committee because its value is substantial and even the perception of conflict of interest could bias the presentation of information. There is no CMS requirement for this disclosure — it is an ethical issue, not a legal one. The fact that the stock was purchased by someone else is irrelevant because you now own it. The fact that you are not a voting member is also irrelevant — presenting information to the committee can still introduce bias.
[/expand]You have 15 vials of a certain drug and your monthly rate is 30 vials per month. There are only 250 vials available in the entire distributor store. What is the most appropriate action?
A. Ask the distributor to send you all 250 vials
B. Implement a protocol to use the 15 vials judiciously
C. Wait until you dispense the total amount and ask a nearby pharmacy to give you more
Explanation: During a drug shortage, ASHP Guidelines recommend implementing conservation strategies, prioritizing use for patients with the greatest need, and communicating transparently with the healthcare team. Requesting all available stock from the distributor deprives other institutions of access. Implementing a usage protocol ensures equitable and medically appropriate distribution of the limited supply.
[/expand]A 60-year-old man managed by a pharmacist-directed lipid clinic would like to receive his laboratory results by email.
What is the most appropriate response?
A. Email communication of protected health information is not acceptable in this situation
B. If the patient signs a consent form acknowledging the risk of potential breaches of privacy and confidentiality, email communication is acceptable C. The patient can email the pharmacist, but HIPAA does not allow the pharmacist to email the patient because protected health information would be disclosed
D. HIPAA requires that the provider set up a secure website for the patient to access any protected health information
Explanation: HIPAA does not prohibit the use of email to communicate with patients. Healthcare providers may communicate PHI via email if the patient requests it and acknowledges the associated privacy risks in writing. HIPAA does not require providers to set up secure websites for patient communication.
[/expand]When chemotherapy is given as curative intent, this reflects which ethical principle?
A. Beneficence
B. Justice
C. Non-maleficence
D. Autonomy
Explanation: Beneficence refers to acting in the best interest of the patient — doing good. Administering chemotherapy with curative intent is an act of beneficence as the aim is to improve the patient's health and achieve a cure.
[/expand]When chemotherapy is withdrawn as palliative intent, this reflects which ethical principle?
A. Beneficence
B. Justice
C. Non-maleficence
D. Autonomy
Explanation: Non-maleficence refers to the principle of "do no harm." Withdrawing chemotherapy in the palliative setting — when continued treatment would cause more harm than benefit — reflects non-maleficence. The decision to stop aggressive treatment and focus on comfort care avoids subjecting the patient to unnecessary harm and suffering.
[/expand]In research on niacin, patients with hyperuricemia or liver disease cannot be recruited due to which ethical principle?
A. Beneficence
B. Justice
C. Autonomy
D. Non-maleficence
Explanation: Non-maleficence requires researchers to protect participants from foreseeable harm. Niacin can worsen hyperuricemia and cause hepatotoxicity. Excluding patients with these conditions protects them from predictable, serious harm.
[/expand]To report a fatal medical device adverse event, which organization should be notified?
A. MedWatch (FDA)
B. ISMP
Explanation: Fatal medical device adverse events must be reported to the FDA through MedWatch. ISMP focuses on medication errors, not medical device failures.
[/expand]To which organization should a serious adverse drug event from a suspected counterfeit medication be reported?
A. National Medication Error Reporting Program (ISMP)
B. The Joint Commission
C. MedWatch (FDA)
D. National Association of Boards of Pharmacy (NABP)
Explanation: Serious adverse drug events from suspected counterfeit medical products should be reported to the FDA through MedWatch. The FDA has the authority and regulatory mandate to investigate and act on suspected counterfeit medications. ISMP handles medication errors but does not have authority over counterfeit medications. TJC requires reporting of sentinel events. NABP accredits online pharmacies but cannot act on counterfeit medications.
[/expand]Reporting side effects that occurred to a patient should:
A. Include patient name and telephone number so the FDA can contact them for follow-up
B. Patient names should not be included because it is protected information
Explanation: When reporting adverse events to MedWatch, patient names should not be included because patient names are protected health information (PHI) under HIPAA. Reports can be submitted using patient identifiers such as initials or case numbers without including full names.
[/expand]Which of the following is considered a sentinel event?
A. Giving the patient a wrong drug
B. Hip replacement surgery on the right side instead of the left
C. Patient fall that led to a bruised elbow
D. Switching a mother's baby that was discovered at the last minute
Explanation: A sentinel event is an unexpected occurrence involving death or serious physical or psychological injury. Wrong-site surgery is a classic example of a sentinel event. Giving the wrong drug may be a medication error but is not automatically a sentinel event unless it results in serious harm. A minor fall with a bruised elbow is a low-severity event. A baby switch discovered before any harm occurred is a near-miss but not a completed sentinel event.
[/expand]A diabetic patient who is non-adherent to his treatment visits your pharmacy and says he forgot his glasses. What is the appropriate action for his next visit?
- Let him go for hospital advice
- Let him go to his primary care provider
- Give the patient more papers to read at home
- Let the patient read and interpret the instructions to evaluate literacy
Explanation: At the next visit when the patient has his glasses, the appropriate action is to assess his health literacy by having him read and interpret the instructions himself. This allows the pharmacist to evaluate his actual comprehension level and tailor education accordingly. Simply providing more written materials without assessing comprehension is inadequate.
[/expand]There were some prescription errors made by certain physicians. What is the best way for the clinical pharmacist to inform them?
A. Open meeting or seminar with all physicians
B. Meeting or seminar with those who made the errors
C. Just keep notes of the mistakes
D. Counsel the physicians to make eligible writing
Explanation: In a just culture, error feedback should be directed specifically to the individuals involved in a confidential, non-punitive, and constructive manner. An open meeting with all physicians is inappropriate because it may embarrass specific individuals and breach confidentiality. Simply keeping notes does not address the problem.
[/expand]A mother gave her child double the prescribed dose. Is this considered a medication error?
A. This should be considered a medication error anyway
B. Not a medication error at all
C. Medication error only if the prescription was written incorrectly
Explanation: A medication error is defined as any preventable event that may cause or lead to inappropriate medication use or patient harm. Administering double the prescribed dose, regardless of who administered it or why, constitutes a medication error. Intent is irrelevant to the classification.
[/expand]What is true regarding adverse event reporting of FDA-approved products to the MedWatch program?
A. Reporting is voluntary
B. Minor adverse events should be reported
C. Serious adverse events caused by vaccine administration should be reported
D. No report should be filed if it is uncertain whether a medication directly caused an adverse event
Explanation: MedWatch solicits voluntary reports about serious adverse events. Reporting to MedWatch by healthcare professionals and consumers is voluntary. Minor adverse events do not require reporting — MedWatch focuses on serious events. Importantly, causality does not need to be proven before reporting — a suspected relationship is sufficient to file a report, making D incorrect.
[/expand]A physician decided to open a pharmacy unit for diabetes for a 6-month pilot trial. Which data should you collect as an outcome indicator?
A. HbA1c at 3 and 6 months
B. Patient knowledge of diabetes and adherence to medication
C. Diabetes mortality rate
Explanation: HbA1c is the primary clinical outcome measure for diabetes management — it directly reflects glycemic control over a 3-month period. Patient knowledge and adherence are process indicators. Mortality rate would be an outcome indicator but is not feasible to measure meaningfully in a 6-month pilot trial for an outpatient diabetes program.
[/expand]According to HIPAA, which of the following items is considered protected health information (PHI)?
A. De-identified information
B. Medical record number
C. Age if under 90 days
D. State of residence
Explanation: A medical record number is a unique identifier that can be used to identify an individual — it is PHI under HIPAA. De-identified information (with all 18 HIPAA identifiers removed) is NOT PHI. Age expressed in years for patients under 90 is generally not PHI. State of residence is generally not considered a HIPAA identifier.
[/expand]Which of the following is an example of a process indicator for a medication use evaluation?
A. Detecting an adverse reaction to antibiotics
B. Ensuring proper timing and dosage of the antibiotics
C. Detecting a defervescence in a neutropenic patient receiving antibiotics
D. Determining the availability of adequately trained laboratory personnel to perform culture and sensitivity
Explanation: A process indicator measures whether the correct actions and procedures are being followed during care delivery. Ensuring proper timing and dosage directly measures the process of care. Detecting an adverse reaction is an outcome indicator. Detecting defervescence is a clinical outcome indicator. Determining the availability of laboratory personnel is a structure indicator.
[/expand]With regard to treatment trials, the primary purpose of the informed consent process is to:
A. Provide information regarding trial participation, treatment, and the financial costs
B. Provide liability coverage for the institution and investigators
C. Serve as a contract between the investigator and the participant
D. Provide sufficient information for a potential subject to make a decision about participating
Explanation: The primary purpose of informed consent is to ensure that potential participants have sufficient, understandable information about the study to make a truly autonomous decision about participation. It is not a legal contract, does not provide liability coverage, and while costs may be discussed, the fundamental goal is respect for autonomy and informed decision-making.
[/expand]An FDA inspector requests records from an IRB that contain confidential patient-specific information. What is the proper course of action?
A. Grant the request, because the FDA inspector is a health professional bound by the same ethical and legal considerations as the IRB
B. Refuse the request, because patients in a study of FDA-regulated products have a guaranteed right of confidentiality
C. Refuse the request, because FDA regulations allow release of confidential patient-specific data only under extraordinary circumstances
D. Grant the request, because the patient's legal right to privacy does not apply to FDA review of research records
Explanation: Under FDA regulations, the FDA has the legal authority to review research records during inspections, including patient-specific information. The privacy rights that normally protect patients do not extend to prevent FDA review of research records for regulatory compliance purposes.
[/expand]Which would be the best quality measure for evaluating a transition of care service from the inpatient to the outpatient setting?
A. The number of patients adherent to their medications 1 year after discharge
B. The number of patients who arrive at their outpatient follow-up visit after discharge
C. The number of patients who are knowledgeable about their medications 6 months after discharge
D. The number of patients who have a medication error during hospitalization out of the total number admitted
Explanation: The most direct and timely quality measure for a transition of care service is whether patients successfully complete their first outpatient follow-up appointment after discharge — this directly reflects the effectiveness of the transition. Adherence and knowledge at 6 months–1 year are too distal to attribute specifically to the transition service. Inpatient medication errors measure inpatient quality, not transition quality.
[/expand]You are a pharmacotherapy specialist and found many medication errors concerning heparin use from physicians. What should you do?
A. Make a weight-based protocol
B. Make educational newsletters for low-performing physicians
C. Make educational newsletters for all physicians
Explanation: In a systems-based approach to medication safety, the most effective intervention is to create a standardized protocol — such as a weight-based heparin dosing protocol — that reduces variability and the opportunity for error. Protocols address the root cause of the errors (lack of standardization) rather than targeting individual behavior.
[/expand]If a pharmacist evaluates a patient's planned drug therapy before dispensing the medication, this is considered a:
A. Concomitant medication use evaluation
B. Prospective medication use evaluation
C. Retrospective medication use evaluation
D. Prevention medication use evaluation
Explanation: A prospective MUE occurs before the medication is dispensed — it evaluates the appropriateness of planned therapy in advance. A concurrent MUE occurs while the patient is receiving therapy. A retrospective MUE reviews therapy that has already been administered.
[/expand]A researcher took a table from a published study, wrote it in handouts with a reference, and distributed it at a conference. This describes:
A. Publication bias
B. Plagiarism
C. Copyright violation
D. Academic dishonesty
Explanation: Reproducing a table directly from a published work — even with a reference — constitutes a copyright violation. Copyright is assigned to the publisher. Reproducing copyrighted material without obtaining written permission from the copyright holder violates copyright law, regardless of proper attribution.
[/expand]A patient with a penicillin allergy was ordered penicillin in the ICU for an infection. He developed anaphylaxis and expired. After informing the medical team, what is the first step?
A. RCA
B. Tell TJC
C. Tell FDA
D. Tell ISMP
Explanation: After a sentinel event — a patient death resulting from a known allergy being ignored — the first step is to conduct a Root Cause Analysis. RCA is a structured process to identify the underlying systems-based causes that allowed the error to occur, with the goal of implementing corrective actions to prevent recurrence.
[/expand]What is true regarding an expanded access protocol?
A. It is a protocol for using a new drug through IND
B. It is a new drug but still not available in pharmacies
C. It is a drug of no cost to patients whose families have less than $20,000 income
D. It is a drug prescribed by a physician through definite medical insurance
Explanation: Expanded access (compassionate use) is a pathway for patients with serious or life-threatening conditions to access investigational drugs outside of clinical trials through an Investigational New Drug (IND) application submitted to the FDA. Patients must provide informed consent. There is no income requirement, and it is not tied to medical insurance.
[/expand]You check a drug (XZ capsule) at the pharmacy store and it has a bad odor. What is your action?
A. Report to FDA MedWatch
B. Joint Commission
C. ISMP
D. State Board
Explanation: A bad odor from a drug capsule is a product quality problem that should be reported to the FDA through MedWatch. MedWatch accepts voluntary reports about product quality issues, including changes in appearance, odor, or texture that may suggest contamination, degradation, or manufacturing problems.
[/expand]A hospital IT team is designing a CPOE program and wants an effective way to enforce the formulary. Which strategy would be most useful?
A. Medication use reviews
B. Drug monographs
C. Drug use evaluations
D. Pop-ups
Explanation: In a CPOE system, pop-up alerts are the most effective real-time tool for formulary enforcement. When a provider orders a non-formulary drug, a pop-up can alert them, suggest formulary alternatives, and require justification for non-formulary use.
[/expand]Secondary research using previously collected blood samples requires which type of IRB review?
A. Expedited review
B. Exempt review
Explanation: Secondary research using previously collected biological specimens that have been de-identified or where the researcher cannot readily ascertain the identity of the subject qualifies for exempt review under the federal regulations for human subjects research protection.
[/expand]According to national patient safety goals (NPSG), which is the correct patient identification practice?
A. Label the drug with name and birth date — 2 patient identifiers
B. Keep drugs out of reach of nurses
Explanation: The Joint Commission's National Patient Safety Goals require the use of at least two patient identifiers before providing care. Acceptable identifiers include the patient's name, assigned identification number, telephone number, date of birth, or other person-specific identifier. Room number alone is NOT an acceptable identifier.
[/expand]Which one is a medication error that should be reported to ISMP?
A. Pharmacist forgets an insulin vial out of the refrigerator
B. Nephrotoxicity after gentamicin
Explanation: Leaving an insulin vial out of the refrigerator is a storage error — a type of medication error involving improper handling of a drug. ISMP receives reports of medication errors including dispensing, storage, preparation, and administration errors. Nephrotoxicity after gentamicin is an expected adverse drug reaction (ADR), not a medication error. ADRs are reported to MedWatch (FDA).
[/expand]Which is a medication error that should be reported to ISMP?
A. Pharmacist dispenses 30 pills for a patient whose prescription reads "2 tablets daily for 30 days"
B. Rash after carbamazepine
Explanation: The prescription for "2 tablets daily for 30 days" requires 60 tablets, but the pharmacist dispensed only 30 — this is a dispensing error (wrong quantity) and a medication error that should be reported to ISMP. A rash after carbamazepine is an expected adverse drug reaction, not a medication error, and would be reported to MedWatch (FDA).
[/expand]HIPAA is enforced by:
A. DHHS Office of Civil Rights
B. Joint Commission
C. NCQA
D. AHRQ
Explanation: HIPAA is enforced by the U.S. Department of Health and Human Services (DHHS) Office for Civil Rights (OCR). The OCR investigates complaints, conducts compliance reviews, and provides education about HIPAA requirements.
[/expand]Which of the following organizations considers HIPAA in its standards?
A. NCOA
B. ISMP
C. TJC (The Joint Commission)
Explanation: The Joint Commission incorporates HIPAA requirements into its accreditation standards for hospitals and healthcare organizations. TJC-accredited institutions are required to comply with HIPAA privacy and security rules as part of their broader compliance obligations.
[/expand]Which drug information resource covers drugs and related substances reported to be of clinical interest anywhere in the world?
A. USP-NF
B. Martindale
C. Micromedex
D. Up-To-Date
Explanation: Martindale: The Complete Drug Reference is a comprehensive tertiary reference that covers drugs and related substances of clinical interest from around the world, including drugs not available or approved in the United States. USP-NF focuses on U.S. drug standards. Micromedex and Up-To-Date focus primarily on clinical decision support for commonly used medications.
[/expand]During watching TV, a patient learns that a certain drug was recalled as a Class I recall. What should you tell her?
A. Ask her not to use it as they have a remote hazard
B. Ask her not to use it as they have a reasonable hazard
C. Tell her to use them as there is no hazard at all
Explanation:
- A Class I recall indicates a reasonable probability that use of the product will cause serious adverse health consequences or death. The patient should immediately stop using the product.
- Class II recall means use may cause temporary adverse health consequences or there is a remote probability of serious consequences.
- Class III recall means use is unlikely to cause adverse health consequences.
A patient returns to your pharmacy with blood glucose testing strips that the FDA has recalled.
A. Return them and tell the patient they are dangerous — they are a Class I Recall
B. Return them and calm the patient — they are a Class III Recall and not dangerous
C. Return them — these strips are a Class II Recall
Explanation: Blood glucose testing strips have been recalled as Class I recalls due to the risk that the strips may provide inaccurate blood sugar readings and potentially cause diabetes patients to suffer serious injury or even death. The patient should immediately stop using the strips and obtain replacements.
[/expand]Class I recall means:
A. Remote serious adverse drug event
B. Reasonable probability of a serious adverse drug event
Explanation: A Class I recall means there is a reasonable possibility that use of the product will cause serious adverse health consequences or death. Class II recalls indicate a remote possibility of serious harm. Class III recalls indicate use is unlikely to cause adverse health consequences.
[/expand]Randomized clinical trial reports should comply with which reporting standard?
A. CONSORT (Consolidated Standards of Reporting Trials)
B. PRISMA
C. MOOSE
Explanation: CONSORT is the reporting guideline specifically designed for randomized controlled trials. PRISMA is for systematic reviews and meta-analyses. MOOSE is for meta-analyses of observational studies.
[/expand]Any submitted meta-analyses should follow which reporting standard?
A. CONSORT
B. PRISMA
Explanation: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) is the standard reporting guideline for systematic reviews and meta-analyses. CONSORT is for randomized clinical trials.
[/expand]PGY2 program accreditation is provided by which organization?
A. ACPE
B. ASHP
C. TJC
D. AHRQ
Explanation: The American Society of Health-System Pharmacists (ASHP) accredits pharmacy residency programs, including PGY1 and PGY2 programs, through its Commission on Credentialing. ACPE accredits pharmacy education programs (colleges of pharmacy). TJC accredits healthcare organizations. AHRQ funds healthcare quality and safety research.
[/expand]The Reducing Prescription Drug Shortages Executive Order signed by President Obama on October 31, 2011 requires the FDA to:
A. Broaden the reporting of manufacturing discontinuities that may lead to shortages of life-supporting drugs to CMS
B. Expedite regulatory reviews to avoid or mitigate existing or potential drug shortages
Explanation: The Executive Order directed the FDA — not CMS — to expedite regulatory reviews to avoid or mitigate existing or potential drug shortages. This includes expedited review of new drug suppliers, manufacturing sites, and manufacturing changes.
[/expand]The outcome indicator for an ICU protocol is:
A. Increase nurse satisfaction
B. Decrease physician workload
C. Decrease patient duration on ventilator
Explanation: An outcome indicator measures the result of care delivered to patients. Decreasing the duration of mechanical ventilation directly reflects patient clinical outcomes and the effectiveness of the ICU protocol.
[/expand]After a medication error is reported to ISMP, what happens next?
A. You should contact MedWatch
B. You should contact the manufacturer
C. ISMP will contact the FDA and the manufacturer
Explanation: After a medication error is reported to ISMP, ISMP analyzes the report, shares information to prevent future errors, and contacts the FDA and manufacturer as appropriate. The reporter does not need to separately contact MedWatch or the manufacturer.
[/expand]Why do adverse effects of a drug appear after marketing?
A. The company does not mention all adverse effects
B. Phase III trials are not large enough or long enough to detect all adverse drug effects
Explanation: Phase III clinical trials typically enroll thousands of patients over months to years. Rare adverse effects, effects requiring long latency periods, and effects in special populations not enrolled in trials may only become apparent through post-marketing surveillance involving millions of patients over many years.
[/expand]To report pulmonary embolism occurring in a woman on combined oral contraceptives, report to:
A. MedWatch (FDA)
B. TJC
C. ISMP
Explanation: A pulmonary embolism associated with combined oral contraceptive use is a serious adverse drug reaction (ADR) and should be reported to the FDA through MedWatch. TJC handles sentinel events in accredited institutions. ISMP handles medication errors, not adverse drug reactions.
[/expand]A patient on opioids has a negative urine drug test, and it is discovered that his son took the drug. To whom should this be reported?
A. Drug Enforcement Administration (DEA)
B. Adult Protective Services
Explanation: The diversion of controlled substances (opioids) is a legal matter that falls under the jurisdiction of the DEA, which regulates the manufacture, distribution, and dispensing of controlled substances. Drug diversion — even within a family — is a federal violation that should be reported to the DEA.
[/expand]What is the correct definition of redundant publication?
A. An article published before
B. Part of it published before in a poster
C. Part of it mentioned before
Explanation: Redundant publication (duplicate publication or self-plagiarism) occurs when an author submits or publishes substantially similar work in more than one journal or publication without appropriate disclosure. Publishing part of a study that was previously presented as a poster without disclosing this to editors constitutes redundant publication.
[/expand]A pharmacist during his presentation shows a table taken from another study with a proper reference. This is considered:
A. Copyright violation
B. Redundant publication
Explanation: Even with proper attribution, reproducing a table directly from a published work without obtaining written permission from the copyright holder (the publisher) constitutes a copyright violation. Copyright is assigned to the publisher, not the author. Proper referencing acknowledges the source but does not replace the need for permission to reproduce copyrighted material.
[/expand]What is true about REMS (Risk Evaluation and Mitigation Strategy)?
A. To confirm drug abuse and misuse do not occur
B. Provision with patient education and sending an educative video
C. Dispensed from a licensed (certified) pharmacy
Explanation: A REMS is an FDA-required safety program for certain drugs with serious safety concerns. A key component of many REMS programs is that the drug can only be dispensed from certified pharmacies that have completed the required REMS training and comply with specific dispensing requirements.
[/expand]Informed consent contains which of the following essential elements?
A. Trial duration
B. Hospital phone number to contact in case of problems
C. Study funding source
D. Patient identification
Explanation: The essential elements of informed consent include a description of the research and its purpose, foreseeable risks and discomforts, expected benefits, disclosure of alternatives, confidentiality protections, compensation information, contact information for questions, and a statement that participation is voluntary. Trial duration is part of the research description. Study funding may be disclosed, but it is not a universally required element in all frameworks.
[/expand]What is true regarding an IRB study about a device for hypertension where pharmacists will publish the result?
A. Exempt review
B. Expedited review
C. Full review
Explanation: Non-invasive diagnostic devices — such as blood pressure monitoring devices — that pose no more than minimal risk undergo expedited IRB review. Full review is required for research involving greater than minimal risk. Exempt review is for very low-risk research categories such as anonymous surveys or educational studies.
[/expand]A researcher wants to estimate accuracy and precision for a new blood pressure device compared to the old device. Results will be announced at a conference. What type of IRB review is required?
A. Investigational peer review
B. Exempt from review
C. Full IRB review
D. Expedited review
Explanation: This study involves a non-invasive diagnostic device, comparison over 2 weeks, and planned public dissemination. Non-invasive diagnostic procedures pose no more than minimal risk and qualify for expedited review. Since the results will be disseminated publicly, it is not exempt. Full IRB review is required only when the research involves more than minimal risk.
[/expand]Which of the following is an example of assent?
A. A 14-year-old boy who wants to participate in a study about weight loss
B. A mother of a 3-year-old girl who participates in a study about a new vaccine
Explanation: Assent is the affirmative agreement of a minor to participate in research when they are old enough to understand the study but are legally unable to provide consent (typically ages 7–17). A 14-year-old can and should provide assent while a parent or guardian provides formal informed consent. A 3-year-old is too young to provide assent — only the parent can provide consent.
[/expand]The management of the integrity of the pharmaceutical supply chain is governed by which of the following?
A. Food Drug and Cosmetic Act
B. Hatch/Waxman Act
C. Drug Quality Security Act
D. Biologics Price Competition and Innovation Act
Explanation: The Drug Quality and Security Act (DQSA) requires the pharmaceutical supply chain to implement medication tracking and tracing, detection of suspicious products, and enforces guidelines for wholesaler licensing and reporting. The Food, Drug and Cosmetic Act focuses on drug efficacy and safety. The Hatch-Waxman Act established the pathway for abbreviated NDAs for generic drugs. The Biologics Price Competition and Innovation Act created a regulatory pathway for biosimilar products.
[/expand]Which could be considered a best practice to manage ongoing oncology drug shortages?
A. Contracts with every commercial wholesaler
B. Insource with compounding generic IV cytotoxic oncolytics
C. Organize a multidisciplinary team that meets regularly to manage drug shortages as they arise
D. Borrow stock from a larger cancer center for drugs on shortage
Explanation: Per ASHP Guidelines for Managing Drug Product Shortages, organizing a multidisciplinary team with standing meetings and decision-making authority to manage ongoing shortages has been identified as a best practice. Contracting with every wholesaler is impractical. Maintaining infrastructure for compounding multiple IV cytotoxic agents exceeds what most institutional compounding centers can reasonably manage. Borrowing stock from larger cancer centers is not viable as they face the same shortages.
[/expand]Which statement is most correct regarding the difference between the FDA approval process for generic drugs and biosimilars?
A. The biosimilar pathway involves drugs with a wide range of molecular weights
B. The endpoint for approval for both is ±20% bioavailability
C. Biosimilars are generated from reproducible steps of chemical synthesis
D. Biosimilars must demonstrate similar safety, purity, and potency
Explanation: The FDA definition of a biosimilar requires the product to show no clinically meaningful difference in terms of safety, purity, and potency compared to the reference biologic. Biosimilars are biologically based complex molecules with HIGH molecular weight. The ±20% bioavailability standard applies only to small molecule generic drugs. Biosimilars are generated from living cell lines, not chemical synthesis.
[/expand]Which time point is recommended for follow-up by a pharmacist for patients starting a new oral oncolytic therapy?
A. Prior to first refill
B. At consistent 6-month intervals
C. With first report of patient toxicity
D. Within 7 to 14 days following starting the drug
Explanation: The HOPA best practices for oral oncolytic therapy and the ASCO/NCODA standards for medically integrated dispensing of oral oncolytics recommend pharmacist follow-up within 7 to 14 days and within 7 days of therapy initiation, respectively. Early follow-up allows assessment of toxicity, adherence, and patient understanding before significant harm can occur.
[/expand]A patient who cannot remember his medications wants the caregiver to help him. According to medication reconciliation guidelines, what should be done?
A. Stop reconciliation at this time
B. Let the caregiver help the patient
C. Reconciliation must assess the patient directly
Explanation: Medication reconciliation guidelines allow and encourage the involvement of caregivers when a patient is unable to accurately recall their medications. The goal of reconciliation is to obtain the most accurate and complete medication list possible. Stopping reconciliation is not acceptable as it leaves the patient at risk for medication errors.
[/expand]You are performing medication reconciliation for a woman who usually forgets her medications and always tells you to ask her husband. What should you do?
A. Stop reconciliation
B. Order her to tell you what she remembers
C. Listen to her husband
Explanation: When a patient consistently relies on a caregiver for medication information and refers you to that person, involving the caregiver is the most appropriate approach to obtain accurate medication history. The goal of reconciliation is accuracy, not strict independence. Stopping reconciliation is unsafe.
[/expand]An elderly patient who cannot speak comes with his son. How should consent be obtained?
A. Caregiver only
B. Patient
Explanation: The inability to speak does not mean the patient is unable to consent. Consent is determined by cognitive capacity and the ability to understand and communicate a decision — not by the ability to verbally speak. A non-verbal patient can communicate consent through writing, nodding, or other means. Only if the patient lacks decision-making capacity should the surrogate decision-maker be involved.
[/expand]Hospital manager wants to know the quality gap from new guidelines to the hospital. What piece of information would help him find that?
A. Number of reduced death
B. Applied protocols for HTN
C. 3 years cost of HTN medications
D. Published in highly trusted journals
Explanation: To identify a quality gap between new clinical guidelines and current hospital practice, the most relevant information is whether current protocols (applied protocols for HTN) align with the new guidelines. This process indicator reveals where practice deviates from evidence-based recommendations, defining the quality gap. Number of deaths and cost data are outcomes and financial measures, not direct measures of guideline adherence.
[/expand]SECTION 4: RESEARCH METHODOLOGY AND STUDY DESIGN
CONCEPTUAL SUMMARY
Understanding study design is fundamental to evaluating medical literature. The hierarchy of evidence from strongest to weakest is generally: systematic reviews and meta-analyses > randomized controlled trials (RCTs) > cohort studies > case-control studies > cross-sectional studies > case series and case reports > expert opinion.
Types of Studies:
- Randomized Controlled Trial (RCT): Subjects randomly assigned to intervention or control. Gold standard for establishing causality.
- Open-label: everyone knows the treatment.
- Single-blind: one party is blinded.
- Double-blind: both subject and investigator are blinded.
- Prospective Cohort: Subjects grouped by exposure status and followed forward in time. Best when exposure is common and outcome is common.
- Retrospective Cohort: Both exposure and outcome have already occurred; data collected from records. Faster but susceptible to information bias.
- Case-Control: Subjects grouped by outcome status; exposure differences examined retrospectively. Best for rare outcomes or limited time. Susceptible to recall bias.
- Cross-Sectional: Measures prevalence simultaneously at one point in time. Cannot establish causality.
- Case Series/Report: Descriptive accounts of one or more patients. Cannot establish causality.
Bias Types:
- Recall bias: Differential recall of past exposures (common in case-control studies).
- Channeling bias: Sicker patients preferentially receive certain treatment, distorting efficacy estimates.
- Misclassification bias: Incorrect assignment of exposure or outcome status.
- Confounding bias: A third variable distorts the apparent relationship.
- Information bias: Inaccurate data from retrospective chart reviews.
Controlling for Confounding: Restriction (reduces external validity), randomization, matching, stratification, and multivariate analysis. Restriction is the only method that reduces external validity.
Validity:
- Internal validity: How well the study was conducted.
- External validity: How well results generalize to other populations (generalizability).
Intention-to-Treat (ITT) Analysis: Analyzes all randomized patients regardless of adherence. Provides the best estimate of effectiveness under typical clinical conditions. May underestimate the true treatment effect.
Per-Protocol (PP) Analysis: Analyzes only patients who adhered to the protocol. Provides the best estimate of efficacy under ideal conditions. May be susceptible to a lack of power.
PRACTICE QUESTIONS — RESEARCH METHODOLOGY AND STUDY DESIGN
A large retrospective cohort study compared a new NSAID with ibuprofen and naproxen. Investigators argue that the lack of difference in safety is because the drug is promoted as safer, and therefore, patients at a higher baseline risk of ulceration receive it. Which potential source of bias is most likely present?
A. Recall bias
B. Misclassification bias
C. Interviewer bias
D. Channeling bias
Explanation: Channeling bias occurs when a drug perceived as safer or more effective is preferentially prescribed to patients at higher risk. In this case, physicians channel higher-risk patients to the new NSAID because it is marketed as safer, making the two groups non-comparable at baseline. This distorts the apparent safety comparison.
[/expand]Researchers study the impact of potential risk factors on breast cancer occurrence. Of the techniques available for controlling confounding variables, which method could ultimately reduce the external validity of the study?
A. Matching
B. Multivariate analysis
C. Restriction
D. Stratification
Answer: C. Restriction
Explanation: Restriction limits the study population to individuals who do not have the confounding variable. This controls confounding but reduces the generalizability (external validity) of the findings because the results only apply to the restricted group. Matching, stratification, and multivariate analysis control for confounding without limiting enrollment.
[/expand]Researchers conduct a randomized, active-comparator clinical trial of two antihypertensive medications where both study subjects and investigators know the identity of the treatment for each subject.
Which study design term best describes this situation?
A. Open-labeled
B. Single-blinded
C. Double-blinded
D. Triple-blinded
Explanation: An open-label study is one in which all study subjects, investigators, and evaluators know which treatment allocation group each subject has been assigned to. Single-blind means either the subject or the investigator is unaware. Double-blind means both are unaware. Triple-blind additionally blinds the data analyst or safety monitoring committee.
[/expand]Oncology colleagues want to determine if there is a difference in exposure to cell phone radiation in patients with neuroblastoma versus those without. They have patients from their neuro-oncology clinic and must complete the research in 6 months.
Which study design would be most appropriate?
A. Case-control
B. Randomized clinical trial
C. Cross-sectional
D. Cohort
Explanation: The colleagues want to start with patients who have neuroblastoma (the outcome is known) and assess differences in radiation exposure (the exposure) between those with and without the disease. This is the classic design of a case-control study. Case-control studies are retrospective and can be completed quickly, making them feasible within the 6-month timeline.
[/expand]A study selected groups of patients based on whether they had received medical care for a fall in the previous 3 years. Both groups were matched on age, preexisting conditions, other medications, and sex. The study assessed antidepressant use in each group.
Which type of trial design was used?
A. Prospective cohort B. Retrospective cohort C. Case-control D. Randomized controlled trial
[expand] Answer: C. Case-controlExplanation: In this study, participants are divided into groups based on whether they experienced a fall (outcome status is known first). Both groups are then assessed for antidepressant use (the exposure). This is the defining feature of a case-control study — groups are defined by outcome, and exposure is examined retrospectively.
[/expand]You are on the P&T Committee. A prospective head-to-head study showed similar efficacy between a new ICU delirium drug and haloperidol with a favorable trend for QT safety. A retrospective analysis showed shorter hospital stay and decreased costs with the new drug. What is your recommendation?
A. Add to formulary because of potential cost savings
B. Add to formulary because of improved safety profile
C. Do not add because retrospective analyses are subject to information bias
D. Do not add because retrospective analyses are subject to misclassification bias
Explanation: Retrospective chart reviews are among the lowest quality evidence and are subject to recall bias and inaccurate or invalid data (information bias). Formulary decisions should be based on high-quality evidence, particularly randomized controlled trials. A single retrospective analysis showing cost savings is insufficient to justify formulary addition.
[/expand]There have been many small reports showing that a drug used to treat cancer also caused hypertension. Which study would provide rapid information regarding this association?
A. Case-control study B. Meta-analysis C. Double-blind trial D. Review article
[expand] Answer: B. Meta-analysisExplanation: A meta-analysis pools data from multiple small studies to provide a combined, more powerful estimate of an effect. When several small studies already exist, a meta-analysis can rapidly synthesize their data, provide a good estimate of whether the association is real, and is more cost-effective and faster than conducting a new double-blind RCT.
[/expand]As the incidence of tuberculosis increases, the most likely effect on prevalence is that it:
A. Increases B. Decreases C. Stays the same D. Cannot be determined from the given information
[expand] Answer: A. IncreasesExplanation: Prevalence is determined by both incidence (the rate of new cases) and duration of disease. As incidence increases, more new cases are being added to the pool of existing cases. Assuming the duration of disease and recovery/death rates remain constant, an increase in incidence will lead to an increase in prevalence. Prevalence = Incidence × Duration.
[/expand]The FDA has asked for phase IV data after marketing of a new ALS drug due to a trend toward increased risk of bronchospasm in early trials. ALS is uncommon and exposure to this agent would be uncommon.
Which study design is most appropriate?
A. A case series B. A randomized controlled trial C. A prospective cohort study D. A retrospective cohort study
[expand] Answer: D. A retrospective cohort studyExplanation: ALS is uncommon — meaning exposure to this agent would be uncommon. This lends itself to a cohort trial (grouping by exposure). A retrospective cohort is preferred over prospective because it can be completed more quickly using existing records. A prospective cohort would take longer. A case series would be descriptive only. An RCT would be unethical given known safety concerns.
[/expand]A formulary drug is being scrutinized because of rare reports of serious drug-induced rhabdomyolysis. The FDA reevaluation will take considerable time. The P&T Committee is considering whether to take the drug off the formulary.
Which study design would best suit this problem?
A. Randomized controlled crossover clinical trial
B. Case-control study
C. Prospective cohort study
D. Randomized controlled parallel-group clinical trial
Explanation: A case-control study is most appropriate when investigating a common exposure (drug is on the market) and a relatively rare outcome (rhabdomyolysis). Randomized controlled trials and prospective cohorts would be unethical given the known serious toxicity and would take too long. Case-control studies can be completed relatively quickly.
[/expand]A study that measures the number of persons with influenza in a calendar year is which type of study?
A. Cohort study
B. Case-control
C. Cross-sectional
D. Case report
Explanation: Measuring the number of persons with influenza in a calendar year is a prevalence study — it counts how many people have the condition at a given time. This is the definition of a cross-sectional study: measuring the prevalence of a condition in a population at a specific point in time.
[/expand]A study enrolled 6,161 individuals with acute pancreatitis and 61,637 without pancreatitis, then retrospectively looked for differences in glucocorticoid use between the study groups.
Which study design best describes this study?
A. Case series
B. Case-control
C. Cohort
D. Cross-sectional
Explanation: The outcome (pancreatitis or no pancreatitis) is known first, and investigators look backward to assess differences in the exposure (glucocorticoid use). This is the defining feature of a case-control study.
[/expand]The Sudden Cardiac Death in Heart Failure trial showed a 7.2% absolute risk reduction and a 23% relative risk reduction in all-cause mortality at 60 months with ICD versus placebo. Which best shows the number of patients needed to treat with an ICD to prevent one death?
A. 1
B. 4
C. 14
D. 43
Explanation: NNT = 1 ÷ ARR = 1 ÷ 0.072 = 13.9, approximately 14 patients. About 14 patients would need to be treated with ICD to prevent one death in 60 months versus placebo.
[/expand]A randomized, double-blind, placebo-controlled trial of patients with DIC showed mortality of 44% in the antithrombin III group versus 56% in the placebo group. What is the NNT to prevent 1 death?
A. 5
B. 8
C. 22
D. 40
Explanation: ARR = 56% − 44% = 12% = 0.12. NNT = 1 ÷ 0.12 = 8.33, rounded to 8 patients.
[/expand]A study reports an odds ratio of 1.18 for ventricular arrhythmia with a new diuretic compared to hydrochlorothiazide. The 95% CI is 1.04 to 1.33.
Which is the correct interpretation?
A. The risk of ventricular arrhythmia may be decreased between 4% and 33%
B. The risk of ventricular arrhythmia may be 4 to 33 times less
C. The risk of ventricular arrhythmia may be elevated between 4% and 33%
D. The risk of ventricular arrhythmia may be 4 to 33 times greater
Explanation: An OR greater than 1 indicates increased risk. The OR of 1.18 indicates an 18% increased risk compared to baseline. The 95% CI of 1.04 to 1.33 means the risk is elevated somewhere between 4% and 33% above baseline. Since the CI does not cross 1, the result is statistically significant.
[/expand]In a cohort study, investigators report the relative risk of autistic disorder in vaccinated versus unvaccinated children as 0.92 (95% CI = 0.65–1.07).
Which p-value is consistent with these findings?
A. p < 0.05
B. p < 0.01
C. p > 0.05
D. p > 0.10
Explanation: The 95% CI of 0.65 to 1.07 includes 1, meaning the result is NOT statistically significant at the 0.05 level. A non-significant result corresponds to a p-value greater than 0.05.
[/expand]The mean difference in diastolic blood pressure between two antihypertensives is 10 mm Hg (95% CI = −15 to 51 mm Hg). The difference was not statistically significant at the 0.05 level.
What number is included in the range of values that allows you to make this decision?
A. 0
B. 1
C. 2
D. 20
Explanation: For a confidence interval around a mean difference (not a ratio), the null hypothesis value is 0 (no difference). Since the 95% CI of −15 to 51 mm Hg includes 0, the result is not statistically significant.
[/expand]A study comparing cholesterol-lowering effects of a new medication versus traditional therapy found no difference in total cholesterol after 1 year. If you wrongly concluded that there is no difference, what type of error would you be making?
A. Type I error
B. Type II error
C. Power
D. α error
Explanation: A Type II error occurs when you conclude there is no difference when in fact a true difference exists — a false negative. This is particularly a concern when a study is underpowered (small sample size). A Type I error occurs when you conclude there IS a difference when there is none — a false positive.
[/expand]When calculating sample size to determine the difference between two means, which element should be considered?
A. Effect size
B. Sensitivity
C. The statistical test that will be used
D. Measurement process
Explanation: Sample size calculation requires the effect size (the minimum clinically meaningful difference to detect), the desired power (1 − β), the significance level (α), and the variability (standard deviation) in the outcome. Effect size is the most fundamental element.
[/expand]A prospective 3-year study randomized 500 patients to Drug A 50 mg daily or placebo. The primary endpoint was stroke development. 88 patients in group A and 95 patients in group B had a stroke.
What would be the appropriate statistical test for analyzing the primary endpoint?
A. Fisher's Exact
B. Chi-Square
C. Student's t-test
D. 2-way ANOVA
Explanation: The primary endpoint — development of a stroke — is a dichotomous (yes/no) nominal variable. Chi-square is the appropriate test for comparing proportions between two independent groups with a large enough sample size. Fisher's Exact is used when expected cell counts are small. Student's t-test compares continuous normally distributed data. ANOVA compares means across three or more groups.
[/expand]A study comparing simvastatin versus pravastatin has a secondary endpoint of the proportion of patients achieving their LDL-c goal per guidelines. Which statistical test is appropriate for this endpoint?
A. McNemar test
B. Chi-square
C. Wilcoxon rank sum
D. Sign test
Explanation: The secondary endpoint — proportion of patients achieving their LDL-c goal — is a categorical (dichotomous) variable. Chi-square is appropriate for comparing proportions between two independent groups.
[/expand]The average weight of 100 patients is 60 kg with a standard deviation of 5 kg. Weights are normally distributed. What is the standard error?
A. 12 kg
B. 0.6 kg
C. 5 kg
D. Larger than the standard deviation
E. Smaller than the standard deviation
Explanation: SE = SD ÷ √n = 5 ÷ √100 = 5 ÷ 10 = 0.5 kg. The SE is always smaller than the SD for sample sizes greater than 1.
[/expand]A research group is analyzing the relationship between various independent patient demographics (age, height, weight, albumin, CrCl) and phenytoin pharmacokinetics. Which is the best statistical test?
A. One-way analysis of variance
B. Analysis of covariance
C. Multiple regression
D. Spearman's rank correlation
Explanation: Multiple regression is used when assessing the relationship between one dependent variable (phenytoin pharmacokinetics) and multiple independent variables (age, height, weight, albumin, CrCl) when all variables are numeric (continuous).
[/expand]A placebo-controlled clinical trial has a mean hemoglobin of 13.7 g/dL with a standard deviation of 1.9 g/dL. Assuming normal distribution, which values would most completely incorporate over 99% of all values?
A. 12.8–14.7 g/dL
B. 11.8–15.6 g/dL
C. 9.9–17.5 g/dL
D. 8.0–19.4 g/dL
Explanation: In a normal distribution, approximately 99.7% of values fall within 3 standard deviations of the mean. Mean ± 3 SD = 13.7 ± (3 × 1.9) = 13.7 ± 5.7 = 8.0 to 19.4 g/dL.
[/expand]The primary outcome of a randomized trial is listed as differences in mean blood pressure between two groups after 8 weeks of treatment.
What type of data is this?
A. Nominal
B. Ordinal
C. Interval
D. Ratio
Explanation: Blood pressure is measured as a continuous variable. Because the zero point for blood pressure is absolute, it is considered ratio data. Ratio data has all the properties of interval data but also has an absolute zero.
[/expand]Researchers are categorizing patients' bowel movements into categories: 1–5 per day, 6–10 per day, or 11+ per day. Which data type best represents these categories?
A. Composite
B. Interval
C. Nominal
D. Ordinal
Explanation: Although the actual count of bowel movements is interval data, forcing the data into fixed categories with an implied rank or order (1–5 < 6–10 < 11+) but with unequal intervals between categories makes the data ordinal — there is magnitude and order, but the intervals between categories are not equal.
[/expand]You are comparing hospitalization rates for asthma exacerbations between patients managed by a clinical pharmacist versus usual care at 1 year. What is the most appropriate statistical test?
A. Chi-square
B. Student t-test
C. ANOVA
D. Wilcoxon signed rank
Explanation: The primary outcome — percentage of hospitalization rates — is a dichotomous (yes/no) nominal variable comparing proportions between two independent groups. Chi-square is the appropriate test for comparing proportions between two independent groups.
[/expand]A study reports a mean of 26 albuterol puffs over 2 weeks in 100 patients, with a standard error of the mean (SEM) of 1. What is the value of the standard deviation?
A. 1
B. 10
C. 100
Explanation: SEM = SD ÷ √n. Therefore SD = SEM × √n = 1 × √100 = 1 × 10 = 10 puffs.
[/expand]A study used FEV1 at baseline, change in FEV1, oxygen saturation, and history of inhaled corticosteroid use to predict which patients would be admitted to hospital. Which statistical technique is appropriate for deriving such a predictive rule?
A. Correlation analysis
B. Survival analysis
C. Regression analysis
D. Analysis of variance
Answer: C. Regression analysis
Explanation: Regression analysis is used to construct predictive models — it allows multiple variables to be combined into a prediction equation for an outcome. Correlation analysis only describes how variables move together. Survival analysis evaluates the probability of experiencing an outcome over time. ANOVA is an inferential test for comparing means.
[/expand]A randomized trial of 32 patients comparing two anticoagulants for DVT prevention reports a p-value of 0.12. What is an important consideration in applying these results?
A. Type I error
B. Type II error
C. Confounding by indication
D. Interviewer bias
Answer: B. Type II error
Explanation: A non-significant result in a small trial (only 32 patients) raises concern about Type II error — failing to detect a true difference due to insufficient power. Type I error is only a concern when a statistically significant difference is found. Confounding and interviewer bias risks are minimized by randomization.
[/expand]A study measures the effects of 3 drug doses on feelings of well-being using a 4-point scale. Correlation analysis gives r = 0.8.
Which is the best interpretation?
A. Increasing doses are highly correlated with increases in well-being
B. Increasing doses cause increases in well-being
C. Increasing doses are highly correlated with decreases in well-being
D. Increasing doses cause decreases in well-being
Explanation: A positive r value of 0.8 indicates a strong positive correlation. Correlation does NOT establish causality, so answers B and D are incorrect. A negative r would indicate an inverse correlation.
[/expand]A study evaluated 100 subjects in Ethiopia for disease after exposure to contaminated pond water.
| Diseased | Not Diseased | Total | |
|---|---|---|---|
| Exposed | 42 | 2 | 44 |
| Not exposed | 21 | 35 | 56 |
| Total | 63 | 37 | 100 |
Which statement most accurately describes the risk ratio comparing the exposed to the unexposed?
A. Subjects exposed were 2.55 times more likely to develop the disease
B. Those exposed were 54% more likely to develop the disease
C. Those unexposed were 62.5% less likely to develop disease
D. Those unexposed were 2.55 times more likely to develop disease
Explanation: RR = (risk in exposed) ÷ (risk in unexposed) = (42/44) ÷ (21/56) = 0.955 ÷ 0.375 = 2.55. The reference group is always the unexposed group. Option D incorrectly reverses the groups.
[/expand]A study is designed to investigate the number of adverse drug events in a group of individuals during a 1-year period. The authors report that five events occurred per 10,000 person-years.
Which measure does this estimate represent?
A. Relative risk
B. Incidence rate
C. Odds ratio
D. Prevalence
Explanation: Incidence rate is the instantaneous rate of developing a disease or event, calculated by dividing the number of new events by the total time at risk (person-time). Expressing five events per 10,000 person-years is the definition of incidence rate.
[/expand]In a cohort study of 1,000 non-smokers and 1,000 smokers, 450 of the smokers and 50 of the non-smokers developed COPD. What is the relative risk of smoking for COPD?
A. 9
B. 1/8
C. 1/9
D. 8
Explanation: RR = (450/1000) ÷ (50/1000) = 0.45 ÷ 0.05 = 9. Smokers are 9 times more likely to develop COPD compared to non-smokers.
[/expand]The HOPE trial revealed a relative risk of 0.78 (95% CI: 0.70–0.86) for MI, stroke, and death from cardiovascular causes with ramipril versus placebo.
Which conclusion provides the best interpretation?
A. 22% of the risk was increased by the use of ramipril
B. 22% of the risk was removed by the use of ramipril
C. 78% of the risk was increased by the use of ramipril
D. 78% of the risk was removed by the use of ramipril
Answer: B. 22% of the risk for having a myocardial infarction, stroke, or death from cardiovascular causes was removed by the use of ramipril
Explanation: RRR = 1 − RR = 1 − 0.78 = 0.22 = 22%. A RR of 0.78 means the ramipril group had 78% of the risk of the placebo group — meaning 22% of the risk was eliminated. Since the CI does not include 1, this is statistically significant.
[/expand]Investigators report using a per-protocol analysis showing no difference in the number of relapses between two MS treatments. Which statement best describes this result?
A. May be susceptible to issues regarding a lack of power
B. Provides a good measure of effectiveness under usual clinical conditions
C. Cannot provide an estimate of the method's effectiveness
D. Was obtained using the most common approach to data analysis for clinical trials
Explanation: Per-protocol analysis includes only patients who adhered to the protocol, effectively reducing the sample size and raising concerns about power — especially if the result is non-significant. Intention-to-treat analysis (not per-protocol) is the most common approach for clinical trials and provides the best measure of effectiveness under typical clinical conditions.
[/expand]The association between low birth weight and maternal smoking is being studied by obtaining smoking histories from women at the first prenatal visit, then assessing birth weight at delivery.
What type of study is this?
A. Clinical trial
B. Cross-sectional
C. Prospective cohort
D. Case-control
E. Retrospective cohort
Explanation: Women are grouped by their smoking status (the exposure) at the beginning of the study and then followed forward in time to assess birth weight (the outcome). The exposure is assessed before the outcome occurs, and participants are followed prospectively.
[/expand]Researchers investigate a possible association between smokeless tobacco and oral lesions among professional baseball players. At spring training camp, each player is asked about tobacco use history and a dentist notes oral lesions at the same time.
What type of study is this?
A. Case-control
B. Cross-sectional
C. Prospective cohort
D. Clinical trial
E. Retrospective cohort
Answer: B. Cross-sectional
Explanation: Both the exposure (tobacco use history) and the outcome (oral lesions) are assessed simultaneously at one point in time (spring training camp). This defines a cross-sectional study — a snapshot in time.
[/expand]In a trial comparing rivaroxaban versus placebo in post-ACS patients, the MI rate was 3.76% in the rivaroxaban group and 4.47% in the placebo group. What is the NNT to reduce the risk of one MI?
A. 70
B. 85
C. 140
D. 195
Explanation: ARR = 0.0447 − 0.0376 = 0.0071 = 0.71%. NNT = 1 ÷ 0.0071 = 140.8, approximately 140 patients.
[/expand]In a study, the odds of disease in the group who smoke is 0.25. This means:
A. Smoking causes disease
B. For every 4 who smoke, 1 has the disease
C. For every 5 who smoke, 1 has the disease
D. The disease occurs 4 times more often in those who smoke
E. A larger sample is needed
Explanation: Odds of 0.25 = 1:4 ratio of diseased to non-diseased among smokers. So out of every 5 smokers (1 diseased + 4 not diseased), 1 has the disease. Odds = P/(1−P). If P = 0.20 (1 in 5), then odds = 0.20/0.80 = 0.25.
[/expand]What type of study design best fits the research question: Does smoking cause low birth weight babies in pregnant women?
A. Randomized clinical trial
B. Case-control study
C. Prospective cohort study
D. Cross-sectional study
Explanation: A prospective cohort study is most appropriate for studying the causal relationship between a common exposure (smoking) and a measurable outcome (birth weight). Women would be grouped by smoking status early in pregnancy and followed to delivery. An RCT would be unethical. A case-control would be less ideal for a common exposure.
[/expand]A new ARB is being studied versus telmisartan. The manufacturer wants to show the new drug is similar to or no worse than telmisartan. The manufacturer does not expect the new drug to be better.
Which study type should be used?
A. Superiority trial
B. Equivalence trial
C. Non-inferiority trial
D. None of the above
Explanation: A non-inferiority trial is designed to show that a new treatment is not meaningfully worse than an established treatment by more than a predefined margin. Since the manufacturer does not claim superiority but wants to demonstrate the new ARB is at least as good as telmisartan, a non-inferiority trial is appropriate.
[/expand]A new enzyme immunoassay for HCV RNA has sensitivity of 95% and specificity of 92%. The prevalence of HCV in a cohort of 500 patients is 40%.
| D+VE | D-VE | Total | |
|---|---|---|---|
| T+VE | 190 | 24 | 214 |
| T-VE | 10 | 276 | 286 |
| Total | 200 | 300 | 500 |
Which best represents the positive predictive value?
A. 75%
B. 89%
C. 92%
D. 96%
Explanation: Prevalence = 40%, so 200 of 500 have HCV. True positives = 200 × 0.95 = 190. False positives = 300 − 276 = 24. PPV = 190 ÷ (190 + 24) = 190 ÷ 214 = 88.7% ≈ 89%.
[/expand]A physician gives a verbal order for "epinephrine 1 amp" which is incorrectly interpreted as 1 mg IV, resulting in cardiac toxicity. Multiple similar cases have occurred. A retrospective observational study of epinephrine medication errors is proposed.
Which is the best study design?
A. Case report
B. Randomized controlled
C. Cohort
D. Cross-sectional
Answer: C. Cohort
Explanation: A cohort study is most appropriate for determining the association between an exposure (medication error/wrong epinephrine dose) and outcome (cardiac toxicity) across multiple cases over time. A case report describes a single event. A randomized controlled study would be unethical and impractical. A cross-sectional analysis collects data at one point in time.
[/expand]You are comparing patients with HCAP criteria treated with HCAP recommendations versus CAP guidelines. The primary outcome is a composite of treatment failure (escalation of care, antibiotic adjustment, mortality).
Which is the most appropriate statistical test?
A. Chi-square test
B. Student t-test
C. Analysis of variance
D. Wilcoxon rank
Explanation: The primary outcome is a composite categorical variable — patients either experienced treatment failure or did not (dichotomous/nominal data). Chi-square is the appropriate test for comparing proportions between two independent groups.
[/expand]A double-blind, placebo-controlled trial of early steroids in ARDS patients showed 20.6% mortality in the steroid group versus 42.6% in the placebo group after 28 days.
Which best depicts the relative risk reduction and NNT?
A. 52%; 2
B. 52%; 5
C. 22%; 2
D. 22%; 5
Explanation: RRR = (42.6% − 20.6%) ÷ 42.6% = 22% ÷ 42.6% = 52%. ARR = 42.6% − 20.6% = 22% = 0.22. NNT = 1 ÷ 0.22 = 4.5 ≈ 5 patients.
[/expand]A pooled analysis compared pregabalin doses for painful diabetic neuropathy. Results: 300 mg — 103/265; 600 mg — 238/507.
| +VE | -VE | Total | |
|---|---|---|---|
| 300 mg | 103 | 162 | 265 |
| 600 mg | 238 | 269 | 507 |
Which best represents the odds ratio for achieving ≥ 50% pain reduction between the 300 mg and 600 mg groups?
A. 8%
B. 12%
C. 72%
D. 83%
Explanation: OR = (103/162) ÷ (238/269) = 0.636 ÷ 0.885 = 0.718 ≈ 0.72 = 72%. The OR of 0.72 indicates that patients in the 300 mg group have 72% of the odds of achieving ≥ 50% pain reduction compared to the 600 mg group.
[/expand]Using the same pregabalin data, which best represents the absolute risk reduction (ARR) between the 300 mg and 600 mg groups?
A. 5%
B. 7%
C. 8%
D. 12%
Answer: C. 8%
Explanation: ARR = (238/507) − (103/265) = 0.469 − 0.389 = 0.081 ≈ 8%.
[/expand]A Cochrane review reported a relative risk of 0.84 (95% CI, 0.72–0.98) for mortality reduction with corticosteroids in pneumococcal meningitis. 168 of 561 in the corticosteroid group died; 203 of 571 in the placebo group died.
Which best depicts the NNT to prevent one death?
A. 2 B. 6 C. 8 D. 17
[expand]Answer: D. 17
Explanation: CER = 203/571 = 0.355. EER = 168/561 = 0.299. ARR = 0.355 − 0.299 = 0.056. NNT = 1 ÷ 0.056 = 17.9 ≈ 17 patients.
[/expand]A study of timolol versus placebo in cirrhosis patients found moderate to serious adverse events occurred in 52/108 timolol patients versus 34/105 placebo patients (p = 0.02).
How many patients would need to be treated with timolol for one to have a moderate or serious adverse event?
A. 6 B. 15 C. 50 D. 127
[expand]Answer: A. 6
Explanation: ARI = 52/108 − 34/105 = 0.481 − 0.324 = 0.157 ≈ 16%. NNH = 1 ÷ 0.16 = 6.25 ≈ 6 patients.
[/expand]A study compared a new rapid group A streptococcal antigen test with throat culture (gold standard) in 1,500 patients:
| Positive Culture | Negative Culture | |
|---|---|---|
| Positive rapid test | 155 | 14 |
| Negative rapid test | 24 | 1307 |
Which best depicts the specificity of the new test?
A. 86.5% B. 91.7% C. 98.2% D. 98.9%
[expand]Answer: D. 98.9%
Explanation: Specificity = TN ÷ (TN + FP) = 1307 ÷ (1307 + 14) = 1307 ÷ 1321 = 98.9%. Specificity measures the proportion of those WITHOUT the disease who test negative.
[/expand]The SOCRATES trial comparing ticagrelor versus aspirin for prevention of recurrent stroke reported HR 0.89 (95% CI 0.78–1.01) for the primary outcome.
Which statement best interprets this result?
A. Ticagrelor decreased the risk of a primary outcome by 11%, but it was statistically nonsignificant B. Ticagrelor increased the risk of a primary outcome by 11%, but it was statistically nonsignificant C. Ticagrelor decreased the risk of a primary outcome by 11%, and it was statistically significant D. Ticagrelor increased the risk of a primary outcome by 11%, and it was statistically significant
[expand]Answer: A. Ticagrelor decreased the risk of a primary outcome within 90 days by 11%, but it was statistically nonsignificant
Explanation: An HR of 0.89 means ticagrelor reduced the hazard of the primary outcome by 11% (1 − 0.89 = 11%). However, the 95% CI of 0.78–1.01 includes 1, meaning the result is NOT statistically significant.
[/expand]You are applying a Vietnamese study of intensified antituberculosis therapy in HIV patients with TB meningitis to your ICU patient with HIV and TB meningitis. Which type of validity is most concerning?
A. Internal validity because the study was conducted only in Vietnamese hospitals B. External validity because the study was conducted only in Vietnamese hospitals C. Internal validity because the study design did not include the standard of care for HIV TB meningitis D. External validity because the study design did not include the standard of care for HIV TB meningitis
[expand]Answer: B. External validity because the study was conducted only in Vietnamese hospitals
Explanation: External validity refers to how well study results generalize to other populations and settings. The study was conducted only in Vietnamese hospitals, which may have different patient demographics, resistance patterns, and standard care practices compared to U.S. settings, limiting its generalizability.
[/expand]A study for endometriosis pain management found 95/120 in group A and 64/113 in group B achieved adequate pain control (p = 0.001).
Which best depicts the NNT?
A. 4 B. 6 C. 8 D. 10
[expand]Answer: A. 4
Explanation: Since p = 0.001 (statistically significant), NNT can be calculated. ARR = (95/120) − (64/113) = 0.792 − 0.566 = 0.226 ≈ 23%. NNT = 1 ÷ 0.23 = 4.34 ≈ 4 patients.
[/expand]A Cochrane review compared H1-antihistamines for chronic spontaneous urticaria. Cetirizine 10 mg: RR 2.72 (95% CI 1.51–4.91). Levocetirizine 20 mg: RR 20.97 (95% CI 1.37–37.60). Desloratadine 20 mg: RR 45.97 (95% CI 1.04–245.04).
Which is the best conclusion?
A. Several antihistamines are effective in the complete suppression of chronic spontaneous urticaria B. No antihistamines are effective C. Several antihistamines are safe and effective D. No antihistamines are safe and effective
[expand]Answer: A. Several antihistamines are effective in the complete suppression of chronic spontaneous urticaria
Explanation: All three drugs showed RR > 1 with 95% CIs that do not cross 1, indicating statistically significant efficacy. No safety data were provided, so no conclusion about safety can be drawn. Options C and D require safety data.
[/expand]You are comparing ejection fraction (EF) between two groups: those who received a heart failure drug and those who did not. EF is recorded as a percentage.
Which type of data and test would be best?
A. Continuous, t-test B. Continuous, chi-square C. Dichotomous, t-test D. Dichotomous, chi-square
[expand]Answer: A. Continuous, t-test
Explanation: Ejection fraction measured as a percentage is a continuous variable. Continuous variables that are normally distributed are most appropriately compared using the t-test for two independent groups. Chi-square is appropriate for categorical/dichotomous data.
[/expand]A randomized trial assesses global functioning using the NYHA functional classification (ordered scale I to IV) in three groups of adults after 6 months of treatment.
Which statistical test is most appropriate?
A. Kruskal-Wallis test B. Wilcoxon signed-rank test C. ANOVA D. ANCOVA
[expand]Answer: A. Kruskal-Wallis test
Explanation: NYHA functional class is an ordinal scale with ordered categories but unequal intervals — it is not continuous. ANOVA and ANCOVA require continuous normally distributed data. The Wilcoxon signed-rank test is appropriate for paired ordinal data. The Kruskal-Wallis test is the nonparametric analog of one-way ANOVA and is appropriate for comparing ordinal data across three or more independent groups.
[/expand]A trial comparing four antihypertensive drugs uses an unpaired t-test to test whether each drug is equal to the others. The investigators conclude hydrochlorothiazide is better than atenolol (p < 0.05) and enalapril is better than hydrochlorothiazide (p < 0.01).
Which statement is most appropriate?
A. Investigators used the appropriate statistical test B. Enalapril is the most effective because it has the lowest p-value C. ANOVA would have been a more appropriate test D. A paired t-test is a more appropriate test
[expand]Answer: C. ANOVA would have been a more appropriate test
Explanation: With four independent groups, the unpaired t-test is not appropriate because conducting multiple pairwise comparisons increases the probability of a Type I error. ANOVA followed by appropriate post-hoc multiple comparison testing is the correct approach when comparing means across three or more independent groups. A lower p-value does not indicate greater clinical importance.
[/expand]In a randomized controlled trial, the difference in hospital readmission rates between groups is 6% (p = 0.01). The investigators conclude a statistically significant difference exists.
Which statement is most consistent with this finding?
A. The chance of making a type I error is 5 in 100
B. The trial does not have enough power
C. There is a high likelihood of having made a type II error
D. The chance of making a type I error is 1 in 100
Answer: D. The chance of making a type I error is 1 in 100
Explanation: The p-value of 0.01 means there is a 1% (1 in 100) probability of observing this difference if the null hypothesis is true — this is the actual Type I error rate. Option A incorrectly states the Type I error is 5%, which corresponds to the a priori α level, not the actual p-value.
[/expand]You are reading a manuscript evaluating obesity's impact on enoxaparin pharmacokinetics using an unpaired t-test to compare BMI between normal and obese subjects.
Which best represents the most appropriate criteria for using this parametric test?
A. Sample sizes in the two groups should be equal B. A t-test is not appropriate because BMI data are ordinal C. The variance of the BMI data must be similar in each group D. Pre-study power should be at least 90%
[expand]Answer: C. The variance of the BMI data must be similar in each group
Explanation: Equal variance (homoscedasticity) is a key assumption for the unpaired t-test. BMI is a continuous variable (not ordinal), so a t-test is appropriate. Sample sizes do not need to be equal. A specific power level is not a prerequisite for using the t-test.
[/expand]A trial evaluating a new asthma controller drug shows a 15% difference in morning FEV1 between men and women (95% CI, 10%–21%).
Which statement is most appropriate?
A. Without a p-value it is not possible to conclude whether results were statistically significant B. There is a statistically significant difference between the men and women (p < 0.05) C. There is a statistically significant difference between the men and women (p < 0.01) D. There is no statistically significant difference between the men and women
[expand]Answer: B. There is a statistically significant difference between the men and women (p < 0.05)
Explanation: When a 95% CI is reported for a mean difference, statistical significance is assessed by whether the CI includes 0. The 95% CI of 10% to 21% does NOT include 0, so the result is statistically significant at the 0.05 level (p < 0.05). Reporting a CI is considered superior to reporting a p-value alone.
[/expand]An early-phase trial of 40 subjects comparing a new HDL-raising drug versus lifestyle modification shows mean HDL of 44 mg/dL (control) versus 49 mg/dL (new drug) at 3 months, with p = 0.08.
Which statement provides the best interpretation?
A. An α < 0.10 a priori would have made the study more clinically useful B. The new drug and active control appear to be equally efficacious C. The new drug is better because it increases HDL to a greater extent D. This study is potentially underpowered
[expand]Answer: D. This study is potentially underpowered
Explanation: The small sample size (only 40 subjects) combined with a non-significant result (p = 0.08) strongly suggests the study may be underpowered. It is inappropriate to conclude equality of efficacy without first confirming adequate power. The new drug cannot be declared better when statistical significance was not achieved.
[/expand]Researchers are comparing the percentage of subjects achieving a blood pressure goal (< 140/90 mm Hg) at 3 months between amlodipine 5 mg (n=50) and amlodipine 10 mg (n=50).
Which is the most appropriate statistical test?
A. Independent samples t-test B. Chi-square or Fisher exact test C. Wilcoxon signed-rank test D. One-sample t-test
[expand]Answer: B. Chi-square or Fisher exact test
Explanation: The primary endpoint — percentage of subjects achieving blood pressure goal — is nominal dichotomous data (achieved goal: yes or no). Chi-square or Fisher exact test is appropriate for comparing proportions between two independent groups.
[/expand]An investigational drug is being compared with an existing drug for anemia treatment. After initial planning to detect a 20% minimum difference, investigators decide they want to detect a 10% difference instead.
Which change to the study parameters is most appropriate?
A. Increase the sample size B. Select an α of 0.001 as a cutoff C. Select an α of 0.10 as a cutoff D. Decrease the sample size
[expand]Answer: A. Increase the sample size
Explanation: To detect a smaller difference (10% vs. 20%), more statistical power is needed. The most common and appropriate way to increase power is to increase the sample size. Decreasing α makes it harder to detect differences. Increasing α uses an unconventional value and increases the risk of Type I error.
[/expand]A recently released statin was the subject of a retrospective case-control study after 20 reports of severe myopathy were sent to MedWatch. Risk factors for myopathy were not assessed.
Which type of bias is this study most susceptible to?
A. Confounding by indication B. Recall bias C. Diagnostic bias D. Misclassification
[expand]Answer: B. Recall bias
Explanation: Recall bias is always a potential concern for case-control studies because of the time that passes between the study and the original exposure. Since risk factors were not included in the study design, this concern is heightened.
[/expand]Which factor will be most affected by the type of bias likely to occur in the above statin myopathy study?
A. External validity B. Internal validity C. Assessment of exposure D. Number of patients needed
[expand]Answer: B. Internal validity
Explanation: Recall bias directly threatens internal validity by introducing systematic error into how the exposure (past drug use and risk factors) is assessed. If patients with myopathy recall their drug use differently than controls, the study's internal validity is compromised.
[/expand]Investigators use an intention-to-treat analysis comparing two diuretics for heart failure, finding no difference in hospitalizations between the groups.
Which statement is most appropriate?
A. May be susceptible to issues regarding recall bias B. Provides a good measure of effectiveness under typical clinical conditions C. Cannot provide an estimate of the method's effectiveness D. May overestimate the actual treatment effect
[expand]Answer: B. Provides a good measure of effectiveness under typical clinical conditions
Explanation: Intention-to-treat (ITT) analysis includes all randomized patients in their originally assigned groups regardless of protocol adherence. This approach provides the best estimate of treatment effectiveness under typical real-world conditions. ITT may underestimate (not overestimate) the true pharmacologic effect. Recall bias is not a concern in randomized trials.
[/expand]A prospective randomized study compared once-daily versus twice-daily enoxaparin for VTE treatment. The 95% CI for the difference in recurrence rates was −1.5% to 4.5%.
Which conclusion is most appropriate?
A. Twice-daily enoxaparin is superior to once daily B. Superiority of twice-daily enoxaparin could not be established over once daily C. Once-daily enoxaparin is not inferior to twice daily D. No conclusion can be drawn because p-values are unavailable
[expand]Answer: B. Superiority of twice-daily enoxaparin could not be established over once daily
Explanation: The 95% CI for the difference in recurrence rates (−1.5% to 4.5%) includes zero, meaning there is no statistically significant difference between the two groups. P-values are not required when 95% CIs are available — statistical significance can be determined from the CI.
[/expand]Based on the enoxaparin study above, should the NNT be calculated?
A. NNT would be 2 B. NNT would be 67 C. NNT would be 152 D. NNT should not be calculated because the result was non-significant
[expand]Answer: D. NNT should not be calculated because the result was non-significant
Explanation: The NNT should not be calculated when the primary endpoint is not statistically significant. Calculating an NNT from a non-significant result implies a meaningful clinical difference when none has been established statistically, which can be misleading.
[/expand]A multicenter RCT compared margarine with alpha-linolenic acid (ALA) versus placebo in 4,837 patients. HR = 0.91 (95% CI, 0.78–1.05) for cardiovascular events.
Which statement is most appropriate?
A. Margarine with ALA statistically significantly reduced cardiovascular events (p < 0.05) B. Margarine with ALA statistically significantly reduced cardiovascular events (p < 0.01) C. Margarine with ALA did not significantly reduce cardiovascular events (p > 0.05) D. Without a p-value, it is not possible to determine significance
[expand]Answer: C. Margarine with ALA did not significantly reduce the risk of cardiovascular events (p > 0.05)
Explanation: The 95% CI of 0.78–1.05 includes 1, indicating the result is NOT statistically significant. For hazard ratios, when the CI crosses 1, p > 0.05. A p-value is not required when a 95% CI is available.
[/expand]In the same ALA trial, for which outcome was the study most likely to have been powered?
A. Differences in the rate of the composite outcome (cardiovascular events) B. Differences in the rate of percutaneous coronary interventions C. Differences in the composite outcome in women D. Differences in the composite outcome in men
[expand]Answer: A. Differences in the rate of the composite outcome (cardiovascular events)
Explanation: Clinical trials are powered to detect differences in their primary endpoints. The primary endpoint in this trial was the composite cardiovascular event rate. Subgroup analyses and individual components of the composite are typically underpowered.
[/expand]In a meta-analysis, the OR for low-dose diuretics versus calcium channel blockers for cardiovascular events was 0.84 (95% CI, 0.75–0.95).
Which is the most appropriate interpretation?
A. Treatment with low-dose diuretics was more effective in preventing cardiovascular disease events B. Treatment with calcium channel blockers was more effective C. The difference is not statistically significant D. The odds of developing cardiovascular events when treating with low-dose diuretics are lower than with calcium channel blockers
[expand]Answer: D. The odds of developing cardiovascular events when treating hypertension with low doses of diuretics are lower than when using calcium channel blockers
Explanation: The OR of 0.84 indicates that the odds of cardiovascular events with low-dose diuretics are lower than with calcium channel blockers. The 95% CI of 0.75–0.95 does not include 1, so this is statistically significant. However, in an observational meta-analysis, we cannot state that one drug is more "effective" — we can only describe the odds.
[/expand]SECTION 5: BIOSTATISTICS
CONCEPTUAL SUMMARY
Data Types: Nominal: Categorical data with no order (e.g., disease yes/no, gender, disease site). Ordinal: Categorical data with a rank order but unequal intervals (e.g., ECOG status, NYHA class, pain scale). Interval: Continuous data with equal intervals but no absolute zero (e.g., temperature in Celsius). Ratio: Continuous data with equal intervals AND an absolute zero (e.g., blood pressure, weight, lab values). Most clinical measurements (hemoglobin, glucose, creatinine) are ratio data.
Choosing the Right Statistical Test:
| Data Type | Groups | Distribution | Test |
|---|---|---|---|
| Continuous | 2 groups, different samples | Normal | Student t-test (unpaired) |
| Continuous | 2 groups, same samples (crossover) | Normal | Paired t-test |
| Continuous | 2 groups, different samples | Non-normal | Wilcoxon rank sum / Mann-Whitney U |
| Continuous | 2 groups, same samples | Non-normal | Wilcoxon signed rank |
| Continuous | ≥ 3 groups, different samples | Normal | ANOVA |
| Continuous | ≥ 3 groups, same samples | Normal | Repeated measures ANOVA |
| Ordinal | 2 groups, different samples | — | Mann-Whitney U |
| Ordinal | ≥ 3 groups | — | Kruskal-Wallis |
| Nominal/Dichotomous | 2 groups, different samples | — | Chi-square or Fisher exact |
| Nominal | 2 groups, same samples | — | McNemar test |
Key Statistical Measures: RR = Risk in exposed ÷ risk in unexposed (cohort studies). OR = Odds of exposure in cases ÷ odds of exposure in controls (case-control studies). HR = Rate of event in treatment group ÷ rate in control group at any given time (survival analyses). HR < 1 means lower rate of event in treatment group (beneficial for adverse outcomes). RRR = 1 − RR (or 1 − HR). ARR = Control event rate − Experimental event rate. NNT = 1 ÷ ARR. NNH = 1 ÷ ARI. NNT should ONLY be calculated when the result is statistically significant.
Confidence Intervals: A 95% CI that does not include 1 (for ratios: RR, OR, HR) or 0 (for differences) indicates statistical significance at the 0.05 level. For ratios: null value = 1. For differences: null value = 0.
Sensitivity and Specificity: Sensitivity = TP ÷ (TP + FN): High sensitivity → few false negatives. Specificity = TN ÷ (TN + FP): High specificity → few false positives. PPV = TP ÷ (TP + FP): Increases with higher prevalence. NPV = TN ÷ (TN + FN): Increases with lower prevalence.
Correlation and Regression: Correlation coefficient (r): Measures strength and direction of linear relationship. Range −1 to +1. Correlation does NOT imply causation. Coefficient of determination (r²): Proportion of variation in Y attributable to X. R² close to 1 means most variation in Y is explained by X.
Meta-Analysis: I² = 0%: no heterogeneity. I² = 25%: low. I² = 50%: moderate. I² ≥ 75%: high. Funnel plot asymmetry suggests publication bias. At least two independent reviewers should screen trials.
Non-inferiority Trials: The entire 95% CI must be above the non-inferiority margin (δ) for non-inferiority to be demonstrated. If the lower bound is also above 0% (or 1 for ratios), superiority is also demonstrated.
Phase I — 3+3 Design: MTD = highest dose level where ≤ 1/6 patients experience DLT. If ≥ 2/6 DLT → stop, MTD is the previous dose level.
PRACTICE QUESTIONS — BIOSTATISTICS
If the study team did not use a structured definition for measurable disease, what type of bias may be occurring?
A. Allocation B. Compliance C. Misclassification D. Selection
[expand]Answer: C. Misclassification
Explanation: Misclassification bias occurs when patients are incorrectly assigned to disease categories due to the absence of structured, standardized definitions. Without a consistent definition for measurable disease, some patients may be incorrectly included or excluded, leading to inaccurate classification of exposure or outcome status.
[/expand]A study evaluating a new therapy for prostate cancer excluded patients with a Gleason score of 7 or higher. What type of bias is the study team trying to prevent?
A. Allocation B. Confounding C. Measurement D. Selection
[expand]Answer: B. Confounding
Explanation: Excluding patients with higher Gleason scores removes a potential confounder. Disease severity could confound the results by affecting both the likelihood of receiving the treatment and the outcome. By restricting enrollment to lower Gleason scores, the researchers reduce confounding by disease severity.
[/expand]A study evaluated at least a 25% reduction in pain as the primary outcome. What type of data is being evaluated?
A. Continuous B. Descriptive C. Nominal D. Ordinal
[expand]Answer: C. Nominal
Explanation: At least a 25% reduction in pain represents a yes/no (dichotomous) outcome — either the reduction occurred or it did not. This is nominal data because it creates two categories without any inherent rank or order between them.
[/expand]A study included participants with ECOG performance status of 0 or 1 only. What type of data is ECOG performance status?
A. Continuous B. Descriptive C. Nominal D. Ordinal
[expand]Answer: D. Ordinal
Explanation: ECOG performance status is an ordinal scale with ranked categories (0 = fully active through 4 = completely disabled). There is a clear rank order between values, but the intervals between categories are not equal.
[/expand]Subjects were randomized (1:1) to a new chemotherapy agent or placebo. Results were not normally distributed. The outcome measured is glucose concentration.
What type of statistical test is most appropriate?
A. Paired t-test B. Student t-test C. Wilcoxon rank sum D. Wilcoxon signed rank
[expand]Answer: C. Wilcoxon rank sum
Explanation: Glucose concentration is continuous data. The study has 2 groups with different samples (parallel design, 1:1 randomization). The data are not normally distributed. For continuous data with 2 independent (different) samples that are not normally distributed, the Wilcoxon rank sum test (Mann-Whitney U) is the most appropriate nonparametric test.
[/expand]Subjects were equally randomized to 2 treatment groups in a trial evaluating a new oral breast cancer agent that causes increased glucose concentrations. Data were normally distributed.
What statistical test is most appropriate for analyzing differences in glucose concentrations between treatment groups?
A. Student t-test B. Mann-Whitney U C. Chi-square D. ANOVA
[expand]Answer: A. Student t-test
Explanation: Glucose concentration is continuous data. The study has 2 groups with different samples (parallel design). The data are normally distributed. For continuous data with 2 independent (different) samples that are normally distributed, the Student t-test (unpaired) is the most appropriate parametric test.
[/expand]A trial evaluates overall survival between a new drug and placebo. What statistical test is most appropriate for analyzing differences in ECOG status between treatment groups?
A. ANOVA B. Mann-Whitney U C. Paired t-test D. Wilcoxon signed rank
[expand]Answer: B. Mann-Whitney U
Explanation: ECOG status is ordinal data (ranked categories with unequal intervals). The study has 2 groups with different samples. For ordinal data with 2 independent groups, Mann-Whitney U is the appropriate nonparametric test.
[/expand]Subjects were enrolled in a crossover trial evaluating 2 new oncology agents and placebo. Results were normally distributed. What statistical test is most appropriate for analyzing differences in bilirubin concentrations?
A. Chi-square B. Wilcoxon rank sum C. ANOVA D. Wilcoxon signed rank
[expand]Answer: C. ANOVA
Explanation: Bilirubin concentration is continuous data. The crossover design means the same subjects receive all treatments (same samples). There are 3 groups (2 agents + placebo). The data are normally distributed. For continuous data with 3 or more groups with the same samples and normal distribution, ANOVA (repeated measures ANOVA) is the correct test.
[/expand]Subjects were their own control in a trial evaluating changes in platelet concentrations from baseline following 2 different oncology medications. Results were normally distributed.
What statistical test is most appropriate?
A. McNemar B. Wilcoxon signed rank C. Paired t-test D. Mann-Whitney U
[expand]Answer: C. Paired t-test
Explanation: Platelet concentration is continuous data. Subjects as their own control indicates a crossover design (same samples). There are 2 groups (2 oncology medications). The data are normally distributed. For continuous data with 2 groups, same samples, and normal distribution, the paired t-test is the most appropriate test.
[/expand]A study evaluated changes in hemoglobin as a safety outcome. What type of data is being evaluated?
A. Continuous B. Descriptive C. Nominal D. Ordinal
[expand]Answer: A. Continuous
Explanation: Hemoglobin concentration (g/dL) is a continuous variable because the units of measure between values remain constant across the spectrum, and there is equal distance between each increment. It can take any value within a range.
[/expand]Subjects received a new chemotherapy agent and 4 weeks later received placebo (with adequate washout). Serum sodium concentrations were measured. Results followed a bell-shaped curve.
What statistical test is most appropriate?
A. Paired t-test B. Student t-test C. Wilcoxon rank sum D. Wilcoxon signed rank
[expand]Answer: A. Paired t-test
Explanation: Serum sodium is continuous data. The crossover design (same subjects receiving each treatment) means same samples. There are 2 groups. The bell-shaped curve indicates normal distribution. For continuous data with 2 groups, same samples, and normal distribution, the paired t-test is the most appropriate test.
[/expand]Subjects (n = 250) were enrolled in a trial evaluating overall survival of a new drug versus placebo (2:1 randomization). Baseline demographics included disease site.
What statistical test is most appropriate for analyzing differences in disease site?
A. ANOVA B. Chi-square C. Mann-Whitney U D. Wilcoxon rank sum
[expand]Answer: B. Chi-square
Explanation: Disease site (e.g., lung, breast, colon) is nominal data — categorical without rank or order. The study has 2 groups (new drug vs. placebo) with different samples. For nominal data with 2 independent groups, chi-square is the most appropriate test.
[/expand]The relative risk of non-muscle invasive bladder cancer recurrence was 0.75 with gemcitabine compared with saline. The HR was 0.66 (95% CI, 0.48 to 0.9).
Calculate the relative risk reduction of non-muscle invasive bladder cancer recurrence.
A. 25% B. 42% C. 66% D. 75%
[expand]Answer: A. 25%
Explanation: RRR = 1 − RR = 1 − 0.75 = 0.25 = 25%. A RR of 0.75 means patients receiving gemcitabine have 75% of the risk of bladder cancer recurrence compared to saline — meaning 25% of the risk was removed.
[/expand]Non-muscle invasive bladder cancer recurred in 67 of 201 gemcitabine patients and 91 of 205 saline patients. The HR was 0.66 (95% CI, 0.48 to 0.9).
Calculate the absolute risk reduction.
A. 11% B. 19% C. 24% D. 44%
[expand]Answer: A. 11%
Explanation: ARR = (91/205) − (67/201) = 0.444 − 0.333 = 0.111 ≈ 11%.
[/expand]Gemcitabine decreased the absolute risk of non-muscle invasive bladder cancer recurrence by 11% and the relative risk reduction by 25%. How many subjects are needed to prevent one recurrence?
A. 36 B. 14 C. 10 D. 4
[expand]Answer: C. 10
Explanation: NNT = 1 ÷ ARR = 1 ÷ 0.11 = 9.09, rounded up to 10. Always round the NNT up to ensure you treat enough patients to prevent one event.
[/expand]Exemestane for breast cancer prevention trial: 7 of 2,285 exemestane patients versus 27 of 2,275 placebo patients developed invasive ER-positive breast cancer. HR 0.27 (95% CI 0.12 to 0.6), p < 0.001.
Calculate the relative risk reduction of invasive ER-positive breast cancer with exemestane versus placebo.
A. 12% B. 25% C. 75% D. 95%
[expand]Answer: C. 75%
Explanation: RR = (7/2285) ÷ (27/2275) = 0.003 ÷ 0.012 = 0.25. RRR = 1 − RR = 1 − 0.25 = 0.75 = 75%.
[/expand]The annual incidence of invasive breast cancer was 0.09% with exemestane and 0.34% with placebo (n = 4,560).
Calculate the absolute risk reduction.
A. 0.02% B. 0.25% C. 0.74% D. 0.81%
[expand]Answer: B. 0.25%
Explanation: ARR = 0.34% − 0.09% = 0.25%.
[/expand]Exemestane decreased the absolute risk of invasive breast cancer by 0.25%. How many subjects are needed to prevent one breast cancer occurrence?
A. 5 B. 11 C. 123 D. 400
[expand]Answer: D. 400
Explanation: NNT = 1 ÷ ARR = 1 ÷ 0.0025 = 400.
[/expand]Exemestane increased the absolute risk of arthritis by 2%. How many subjects will be needed to have one report of arthritis?
A. 2 B. 5 C. 50 D. 75
[expand]Answer: C. 50
Explanation: NNH = 1 ÷ ARI = 1 ÷ 0.02 = 50.
[/expand]A study evaluated OS associated with trametinib vs standard of care in low-grade serous ovarian cancer. OS result: HR 0.76 (95% CI, 0.51 to 1.12).
What is the best interpretation?
A. There is no difference in OS between the treatment groups B. OS is longer with SOC C. OS is longer with trametinib D. More information is needed to interpret these results
[expand]Answer: A. There is no difference in OS between the treatment groups
Explanation: The 95% CI of 0.51 to 1.12 includes 1, meaning the result is NOT statistically significant. Although the HR of 0.76 numerically favors trametinib, the wide CI crossing 1 means this difference could be due to chance.
[/expand]A study evaluated PFS associated with trametinib vs SOC in low-grade serous ovarian cancer. PFS result: HR 0.48 (95% CI, 0.36 to 0.64).
What is the best interpretation?
A. PFS is the same for trametinib and SOC B. PFS is longer with SOC C. PFS is longer with trametinib D. The results are inconclusive
[expand]Answer: C. PFS is longer with trametinib
Explanation: The 95% CI of 0.36 to 0.64 does NOT include 1, meaning the result IS statistically significant. The HR of 0.48 indicates that the rate of progression or death is 52% lower with trametinib compared to SOC. Therefore, PFS is significantly longer with trametinib.
[/expand]A meta-analysis (n = 6 trials) evaluated immune checkpoint inhibitors in patients with pre-existing ILD and NSCLC. Objective response rate: 1.99 (95% CI, 1.31 to 37; I² = 0%).
What statement is most appropriate regarding this meta-analysis?
A. The databases used to find eligible articles were sufficient B. Additional trials should have been included C. There is a moderate degree of heterogeneity between the included trials D. A forest plot is needed to interpret the results
[expand]Answer: A. The databases used to find eligible articles were sufficient
Explanation: The I² statistic of 0% indicates no heterogeneity between the included trials — the results are highly consistent across studies. A forest plot is a visual representation of the result but is not needed to interpret the HR and CI provided.
[/expand]A meta-analysis evaluated checkpoint inhibitor pneumonitis in patients with pre-existing ILD. Two individuals reviewed trials with a third as tiebreaker. Grade 3+ pneumonitis: OR 2.91 (95% CI, 1.47 to 5.74; I² = 0%).
What statement is most appropriate?
A. Publication bias is present so you cannot trust the results B. More individuals were needed to assess trial eligibility C. No heterogeneity exists between the trials D. Additional trials should have been included
[expand]Answer: C. No heterogeneity exists between trials
Explanation: The I² statistic of 0% indicates no heterogeneity between included trials — results are consistent across studies. Two independent reviewers with a tiebreaker is an acceptable approach. A funnel plot should be provided to assess publication bias, but its absence does not automatically indicate publication bias is present.
[/expand]A non-inferiority trial compared fosnetupitant vs fosaprepitant for CINV prevention. Non-inferiority margin was −10%. Superiority if > 0%. Result: 4.1% (95% CI, −2.1% to 10.3%).
What is the most accurate interpretation?
A. There is no difference between fosnetupitant and fosaprepitant B. Fosnetupitant is noninferior to fosaprepitant C. Fosnetupitant is superior to fosaprepitant D. Fosnetupitant is noninferior and superior to fosaprepitant
[expand]Answer: B. Fosnetupitant is noninferior to fosaprepitant
Explanation: For non-inferiority with a margin of −10%, the entire 95% CI must be above −10%. The CI of −2.1% to 10.3% does not include −10%, so non-inferiority is demonstrated. For superiority, the lower bound of the CI must be above 0%. The lower bound is −2.1%, which is below 0%, so superiority is NOT demonstrated.
[/expand]A noninferiority trial (non-inferiority margin −10%) concluded fosnetupitant was noninferior to fosaprepitant. Which result most accurately reflects this conclusion?
A. 4.1% (95% CI, −2.1% to 10.3%) B. −3.6% (95% CI, −10.3% to 2.1%) C. 1.3% (95% CI, −10.3% to 10.3%) D. −5.7% (95% CI, −12% to −0.87%)
[expand]Answer: A. 4.1% (95% CI, −2.1% to 10.3%)
Explanation: For non-inferiority with a margin of −10%, the entire 95% CI must be above −10%. Option A: CI −2.1% to 10.3% — does not include −10% ✓ Non-inferior. Option B: CI −10.3% to 2.1% — touches the margin ✗. Option C: CI −10.3% to 10.3% — includes −10% ✗. Option D: CI −12% to −0.87% — below 0% indicating inferiority ✗.
[/expand]A study (n = 9,989) evaluates a new test for colorectal cancer screening. The new test identified CRC in 379 patients. Colonoscopy identified CRC in 823 patients. The PPV is 23.6%.
| Colonoscopy + | Colonoscopy − | Total | |
|---|---|---|---|
| Test + | 379 | 1,227 | 1,606 |
| Test − | 444 | 7,939 | 8,383 |
| Total | 823 | 9,166 | 9,989 |
What is the sensitivity of the diagnostic test?
A. 23.6% B. 46.1% C. 86.6% D. 94.7%
[expand]Answer: B. 46.1%
Explanation: Sensitivity = TP ÷ (TP + FN) = 379 ÷ (379 + 444) = 379 ÷ 823 = 0.461 = 46.1%.
[/expand]Using the same colorectal cancer screening study, what is the negative predictive value?
A. 3.8% B. 8.2% C. 76.4% D. 94.7%
[expand]Answer: D. 94.7%
Explanation: NPV = TN ÷ (TN + FN) = 7,939 ÷ (7,939 + 444) = 7,939 ÷ 8,383 = 0.947 = 94.7%.
[/expand]The coefficient of determination is 0.96 and the correlation coefficient is 0.98 for a study evaluating alopecia with a new chemotherapy agent for breast cancer.
What statement is accurate?
A. More alopecia as the dose increases B. Less alopecia as the dose increases C. Alopecia is not affected by increasing the dose D. Need more information to answer
[expand]Answer: A. More alopecia as the dose increases
Explanation: The coefficient of determination (r²) of 0.96 indicates that 96% of the variation in alopecia is explained by the dose — a very strong relationship. The correlation coefficient (r) of 0.98 is positive, indicating that as dose increases, alopecia also increases (positive relationship).
[/expand]A study team asks for advice on a primary outcome for a phase 3 trial evaluating PFS in colon cancer following a new oral agent. The team wishes to randomize 648 participants.
Which statement is most correct?
A. Longer follow-up is needed B. Larger sample population is required C. Complete response is a more appropriate primary outcome D. The primary outcome is susceptible to assessment-time bias
[expand]Answer: D. The primary outcome is susceptible to assessment-time bias
Explanation: Progression-free survival (PFS) is more susceptible to assessment-time bias than overall survival because it may be difficult to precisely determine the date of disease progression. Generally, PFS requires smaller sample sizes and shorter follow-up than OS. Complete response is a surrogate endpoint that does not always correlate with direct clinical benefit.
[/expand]A study team asks for advice on a phase 3 trial evaluating overall survival in renal cell carcinoma with 525 participants.
Which statement is most correct?
A. Longer follow-up is needed B. Complete response is a more appropriate primary outcome C. Smaller sample population is required D. The primary outcome is more susceptible to bias
[expand]Answer: A. Longer follow-up is needed
Explanation: Overall survival (OS) requires a longer follow-up because patients must die for the event to be captured. OS is the most objective and widely accepted primary endpoint for oncology trials and is less susceptible to bias than PFS.
[/expand]A phase I clinical trial uses a standard 3+3 titration design:
Dose level 1: 0.5 mg/kg — 0/3 DLT Dose level 2: 1 mg/kg — 0/3 DLT Dose level 3: 1.5 mg/kg — 1/3 DLT → 3 more enrolled → 0/3 DLT Dose level 4: 2 mg/kg — 1/3 DLT → 3 more enrolled → 1/3 DLT
Which dose level would be considered the MTD?
[expand]Answer: Dose level 3 (1.5 mg/kg) is the Maximum Tolerated Dose
Explanation: In the standard 3+3 design, the MTD is the highest dose level where 1 or fewer out of 6 patients experience a DLT. At dose level 3: 1/6 DLT ≤ 1/6 → acceptable, escalate. At dose level 4: 2/6 DLT ≥ 2/6 → DLT threshold exceeded, STOP. Therefore, dose level 3 (1.5 mg/kg) is the MTD.
[/expand]A new colorectal cancer screening test has specificity of 84% and sensitivity of 92%.
Which statement is most accurate?
A. High likelihood to miss a diagnosis B. Expect fewer false negatives C. Expect many false positives D. Low likelihood to make a positive diagnosis
[expand]Answer: B. Expect fewer false negatives
Explanation: High sensitivity (92%) means the test correctly identifies most people who truly have the disease — resulting in fewer false negatives. High specificity (84%) means fewer false positives. A high-sensitivity test is good for ruling OUT disease (when negative, reliably rules out).
[/expand]A study (n = 9,989) evaluates a new CRC screening test. The test identified CRC in 60 patients. Colonoscopy identified CRC in 65 patients. PPV is 3.7%.
| Colonoscopy + | Colonoscopy − | Total | |
|---|---|---|---|
| Test + | 60 | 1,561 | 1,621 |
| Test − | 5 | 8,363 | 8,368 |
| Total | 65 | 9,924 | 9,989 |
What is the negative predictive value?
A. 83.7% B. 84.3% C. 92.3% D. 99.9%
[expand]Answer: D. 99.9%
Explanation: NPV = TN ÷ (TN + FN) = 8,363 ÷ (8,363 + 5) = 8,363 ÷ 8,368 = 99.9%.
[/expand]The correlation coefficient is 0.98 and the coefficient of determination is 0.96 for a study evaluating a new chemotherapy agent to treat advanced pancreatic cancer.
What percentage best estimates the variation in the outcome due to the independent variable?
A. 2% B. 19% C. 96% D. 98%
[expand]Answer: C. 96%
Explanation: The coefficient of determination (r²) estimates the proportion of variation in the dependent variable (outcome) that is explained by the independent variable. An r² of 0.96 means 96% of the variation in the outcome is explained by the independent variable.
[/expand]The coefficient of determination is 0.98 for a study evaluating if continued smoking affects complete response (CR) of small cell lung cancer. The alpha level is set at < 0.05. The p-value was determined to be 0.052.
What is the best interpretation?
A. Smoking positively impacts CR B. Smoking negatively impacts CR C. Smoking has no effect on CR D. The results are inconclusive
[expand]Answer: C. Smoking has no effect on CR
Explanation: Although r² of 0.98 suggests a very strong relationship strength, the p-value of 0.052 exceeds the predetermined alpha level of 0.05 — the result is NOT statistically significant. Since the result is not significant, smoking cannot be concluded to have an effect on CR. Regression cannot show direction of a relationship — only strength.
[/expand]A study evaluated PFS associated with bevacizumab plus olaparib or placebo as first-line maintenance in ovarian cancer. Authors concluded PFS was longer with olaparib.
Which result supports the authors' conclusion?
A. HR 0.59 (95% CI, 0.49 to 0.72) B. HR 0.85 (95% CI, 0.58 to 1.25) C. HR 1.15 (95% CI, 0.98 to 1.29) D. HR 1.21 (95% CI, 1.03 to 1.38)
[expand]Answer: A. HR 0.59 (95% CI, 0.49 to 0.72)
Explanation: For PFS, an HR < 1 means olaparib has a lower rate of progression or death (favorable). The 95% CI must not cross 1 for statistical significance. Option A: HR 0.59 with CI 0.49–0.72 — does not cross 1, statistically significant, HR < 1 (favors olaparib) ✓.
[/expand]A meta-analysis (n = 19 trials) evaluated PD-1 vs PD-L1 inhibitors in adults with cancer. The funnel plot displayed asymmetry. No difference in overall PFS: HR 0.62 (95% CI, 0.37 to 1.05; I² = 83%, p < 0.001).
What statement is most appropriate?
A. Publication bias is not present B. More individuals were needed to assess trial eligibility C. Additional tests should have been included D. Heterogeneity exists between trials
[expand]Answer: D. Heterogeneity exists between trials
Explanation: The I² statistic of 83% and Q test p-value < 0.001 indicate high heterogeneity among trials. The asymmetric funnel plot suggests potential publication bias (not its absence). More trials and more reviewers are not necessarily needed.
[/expand]A non-inferiority trial (n = 441) compared palonosetron IV infusion versus IV bolus for CINV. Non-inferiority margin −15%. Per-protocol analysis risk difference: −3.4% (99% CI, −12% to 5.2%).
What statement is most accurate?
A. The incorrect non-inferiority margin was used B. IV infusion is noninferior to IV bolus C. Trial did not meet power so conclusion is invalid D. Conduct PPA before intention-to-treat analysis
[expand]Answer: B. IV infusion is noninferior to IV bolus
Explanation: For non-inferiority with margin −15%, the entire 99% CI must be above −15%. The CI of −12% to 5.2% does not include −15%, so non-inferiority is demonstrated. Since non-inferiority is demonstrated, power considerations do not invalidate the conclusion.
[/expand]The correlation coefficient is 0.95 and the coefficient of determination is 0.90 for a study evaluating vomiting with increasing doses of a new chemotherapy agent for metastatic NSCLC.
What statement is accurate?
A. Less vomiting as the dose increases B. More vomiting as the dose increases C. Vomiting is not affected by increasing dose D. Need more information to determine
[expand]Answer: B. More vomiting as the dose increases
Explanation: The correlation coefficient (r) of 0.95 is positive, indicating that as dose increases, vomiting also increases. The r² of 0.90 means 90% of the variation in vomiting is explained by the dose — a very strong relationship.
[/expand]A study team asks for advice on a primary outcome of overall survival for a phase 3 breast cancer trial with a new oral agent.
Which statement is most correct?
A. Shorter follow-up is needed B. PFS is a better primary outcome C. Confounders during follow-up may affect results D. Overall survival is more susceptible to bias
[expand]Answer: C. Confounders during follow-up may affect results
Explanation: In long-term OS trials, confounders during the extended follow-up period — such as crossover to other treatments, new comorbid conditions, or subsequent therapies — can affect the outcome. OS requires longer follow-up and is less susceptible to bias than PFS.
[/expand]SECTION 6: ONCOLOGY PRACTICE STANDARDS
CONCEPTUAL SUMMARY
USP <800> — Hazardous Drug Handling: Applies to every setting where hazardous drugs (HDs) are handled by healthcare personnel. "Must" indicates a requirement; "should" indicates a recommendation. Institutions must maintain and update an institutional HD list at least annually. The list does not need to mirror the NIOSH list exactly. Chain of custody covered: receipt through final disposal. Characteristics of a hazardous drug: carcinogenicity, teratogenicity, genotoxicity, reproductive toxicity, organ toxicity at low doses, or structural similarity to known HDs. Genotoxicity is the key criterion. Myelosuppression and mucositis are NOT criteria.
PPE Requirements per USP <800>: Compounding sterile HDs: Double gloves (outer sterile), laminate-coated gown, eye/face protection only when working outside a C-PEC or at eye level. Administration: Double gloves required. Laminate gowns required. CSTDs required when dosage form allows. N-95 respirator only for HD spills, cleaning beneath C-PEC work surfaces, or known/suspected airborne HD exposure. All PPE must be discarded as hazardous waste after HD handling.
Compounding HD Sterile Products: Must be prepared in a BSC in a negative pressure room. NEVER in a LAFW or a positive pressure room.
Hazardous Waste (RCRA): FDA-approved nicotine replacement therapies (patches, gum) may be discarded as non-hazardous waste per the Hazardous Waste Pharmaceuticals amendment to RCRA. Warfarin, cyclophosphamide, and melphalan remain U-listed hazardous waste drugs.
NIOSH List Groups: Group 1: Antineoplastic drugs (e.g., pertuzumab, cyclophosphamide). Group 2: Non-antineoplastic drugs with reproductive risk (e.g., azathioprine, tacrolimus). Fluconazole is NOT a NIOSH Group 1 drug.
ASCO/ONS Safety Standards: Domain 3: No verbal orders for chemotherapy (except to hold or stop); policy for intrathecal chemotherapy preparation; out-of-standard regimens must be approved by a second practitioner. Domain 4: Tracking cumulative doses of chemotherapy with significant end-organ toxicity. Does NOT address guidelines for preparation and handling of hazardous drugs.
QOPI Certification: Requires self-reporting of core measures AND a mandatory on-site ASCO site visit. Core measures limited to lung, prostate, breast, colon, and gynecologic oncology. Institutional staff (not ASCO staff) perform chart data abstraction.
CMS Oncology Care Model (OCM) / Enhancing Oncology Model (EOM): Quality metrics include ER visit rates during treatment and in last 30 days of life. New EOM component: health equity plan and reporting of disparities data.
340B: Covered entities include rural hospitals, children's hospitals, and teaching hospitals. Cancer research centers are NOT automatically covered.
Biosimilar Adoption Barriers (ASCO): The most important concern is that interchangeability mandates pharmacy substitution decisions. ASCO does NOT mandate post-marketing safety studies for each biosimilar.
PRACTICE QUESTIONS — ONCOLOGY PRACTICE STANDARDS
Which statement is most correct regarding the difference between the FDA approval process for generic drugs and biosimilars?
A. The biosimilar pathway involves drugs with a wide range of molecular weights B. The endpoint for approval for both is ±20% bioavailability C. Biosimilars are generated from reproducible steps of chemical synthesis D. Biosimilars must demonstrate similar safety, purity, and potency
[expand]Answer: D. Biosimilars must demonstrate similar safety, purity, and potency
Explanation: The FDA definition of a biosimilar requires the product to show no clinically meaningful difference in terms of safety, purity, and potency compared to the reference biologic. Biosimilars are biologically based complex molecules with HIGH molecular weight. The ±20% bioavailability standard applies only to small molecule generic drugs. Biosimilars are generated from living cell lines, not chemical synthesis.
[/expand]Which of the following is NOT addressed in the ASCO/ONS safety standards with relevance to oncology pharmacy practice?
A. Guidelines for preparation and handling of hazardous drugs B. Adjudication of verbal orders for chemotherapy regimens C. Policy requirements for preparation of intrathecal chemotherapy D. Tracking of cumulative doses of chemotherapy drugs with significant end-organ toxicity
[expand]Answer: A. Guidelines for preparation and handling of hazardous drugs
Explanation: The 2016 ASCO/ONS safety standards do NOT address safe handling of hazardous drugs or engineering controls — this is covered by USP <800> and NIOSH guidelines. Domain 3 states that no verbal orders for chemotherapy should be accepted (except to hold or discontinue). Domain 3 also requires a policy for preparation of intrathecal chemotherapy. Domain 4 requires tracking cumulative doses of chemotherapy drugs with significant end-organ toxicity.
[/expand]Which is most correct regarding QOPI certification?
A. On-site reviewers from ASCO will abstract chart data for compliance B. Reported core measures are the sole criteria for QOPI certification C. Core measures are required for each malignancy with NCCN treatment guidelines D. Institutions are required to undergo a site visit by ASCO to be surveyed on compliance with ASCO/ONS safety standards
[expand]Answer: D. Institutions are required to undergo a site visit by ASCO to be surveyed on compliance with ASCO/ONS safety standards
Explanation: Site visits are a required component for QOPI certification. Institutional staff (not ASCO staff) perform chart data abstraction for core measures. Performance on core measures alone is not sufficient — the site visit is also required. Core measure reporting is limited to lung, prostate, breast, colon, and gynecologic oncology.
[/expand]Which is most correct regarding core measures assessed by QOPI?
A. On-site reviewers from ASCO will abstract chart data for compliance B. Reported core measures are the sole criteria for QOPI certification C. Core measures are required for each malignancy with NCCN guidelines D. Institutions are required to self-report compliance with core measures to ASCO ahead of an on-site visit
[expand]Answer: D. Institutions are required to self-report compliance with core measures to ASCO ahead of an on-site visit
Explanation: Institutions must collate data from selected patient charts on compliance with QOPI core measures and submit to ASCO for review prior to an on-site certification visit. Institutional staff (not ASCO staff) perform the data abstraction. The site visit is also required for certification.
[/expand]Which is a new component of the CMS Enhancing Oncology Model (EOM)?
A. Appropriateness of prescribing erythroid colony-stimulating factors B. Percentage of patients who utilize the emergency room during cancer treatment C. Number of patients a practice enrolls in NCI-sponsored phase III clinical trials D. Intentional reaching out to patients with health disparities
[expand]Answer: D. Intentional reaching out to patients with health disparities
Explanation: The EOM requires providers to establish a health equity plan and report disparities data to CMS — this is a NEW component. ER visit rates during treatment and in the last 30 days of life are OCM quality metrics (not new to EOM).
[/expand]Which are quality metrics that oncology practices in the CMS Oncology Care Model are required to submit to CMS?
A. Appropriateness of prescribing erythroid colony-stimulating factors B. Percentage of patients who utilize the emergency room during cancer treatment C. Number of patients enrolled in NCI-sponsored phase III clinical trials D. Patient compliance with oral oncolytic therapy
[expand]Answer: B. Percentage of patients who utilize the emergency room during cancer treatment
Explanation: The OCM requires reporting of emergency room visits during specific treatment episodes AND emergency department usage during the last 30 days of life as reportable quality metrics.
[/expand]Which best summarizes the requirements for maintaining a hazardous drug list per USP <800>?
A. The institution can opt out if they have a low volume of chemotherapy patients B. The institution is required to prepare a HD list and update it annually C. The HD list must mirror the NIOSH list exactly D. Investigational agents are exempt from the institutional HD list
[expand]Answer: B. The institution is required to prepare a HD list and update it at least annually
Explanation: USP <800> mandates that all institutions maintain a hazardous drug list and update it at least annually regardless of chemotherapy volume. Institutions have flexibility to deviate from the NIOSH list based on their own internal risk assessment. Investigational agents must undergo risk assessment — they are NOT exempt.
[/expand]According to USP <800>, which is most correct regarding PPE requirements?
A. Double gloving is required only for compounding of HDs B. Laminate-coated gowns are only required for administration of HDs C. Eye and face protection is required when working outside of a C-PEC or at eye level with HDs D. PPE that has not been subject of a spill event is not required to be disposed of as hazardous waste
[expand]Answer: C. Eye and face protection is required when working outside of a C-PEC or at eye level with HDs
Explanation: Double gloves are required for ALL HD handling activities (compounding AND administration). Laminate gowns are required for activities beyond administration, including dispensing. ALL PPE must be discarded as hazardous waste following HD handling activities — regardless of whether a spill occurred.
[/expand]Which FDA-approved agent can now be discarded as non-hazardous waste because of the Hazardous Waste Pharmaceuticals amendment to RCRA?
A. Warfarin B. Cyclophosphamide C. Nicotine patches D. Melphalan
[expand]Answer: C. Nicotine patches
Explanation: The Hazardous Waste Pharmaceuticals amendment to RCRA allows FDA-approved nicotine replacement therapies (patches, gum) to be discarded as non-hazardous waste. Warfarin, cyclophosphamide, and melphalan remain U-listed hazardous waste drugs.
[/expand]Which is most correct about the practice settings in which USP <800> applies?
A. Only applies in hospitals or cancer clinics that administer hazardous drugs B. Applies in every setting in which hazardous drugs are handled by healthcare personnel C. Applies in hospitals and ambulatory infusion clinics but not veterinary practices D. Only applies to licensed healthcare personnel in hospitals
[expand]Answer: B. Applies in every setting in which hazardous drugs are handled by healthcare personnel
Explanation: USP <800> applies to ALL settings where HDs are handled, including hospitals, physician-owned ambulatory infusion centers, veterinary clinics, and home healthcare settings. It also covers non-licensed personnel such as environmental services employees.
[/expand]Which characteristic is essential to qualify a drug as hazardous?
A. Myelosuppression B. Genotoxicity C. Mucositis D. Immune-mediated hepatitis
[expand]Answer: B. Genotoxicity
Explanation: Genotoxicity is one of the criteria listed by both ASHP and NIOSH for classifying a drug as hazardous. The NIOSH criteria include carcinogenicity, teratogenicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or structural similarity to existing HDs. Myelosuppression and mucositis are documented toxicities but are NOT classification criteria.
[/expand]Which is the most appropriate setting for admixing HD compounded sterile products (CSPs)?
A. BSC in a positive pressure room B. BSC in a negative pressure room C. LAFW in a positive pressure room D. LAFW in a negative pressure room
[expand]Answer: B. BSC in a negative pressure room
Explanation: USP <800> requires HD CSPs to be prepared in a BSC externally vented in a negative pressure environment. A LAFW is never appropriate for compounding HD CSPs because it directs airflow toward the compounder. A positive pressure environment is never appropriate for HD compounding as it pushes contaminated air outward.
[/expand]According to USP <800>, which PPE is required when compounding all sterile HDs?
A. Two pairs of chemotherapy gloves B. Face shield C. N-95 respirator D. Isolation gowns
[expand]Answer: A. Two pairs of chemotherapy gloves
Explanation: USP <800> requires double-gloving (two pairs of chemotherapy-resistant gloves) during all sterile compounding activities, with the outer glove being sterile. A face shield is only required when there is a risk for spills or splashes. An N-95 respirator is only required for HD spills or known/suspected airborne HD vapor exposure. Isolation gowns do not provide adequate protection.
[/expand]The ASCO standards for safe handling of hazardous drugs call for more research in which area?
A. The need for negative pressure rooms when compounding hazardous drugs B. Use of double-gloving with an outer sterile glove when compounding sterile HD products C. Generation of an institutional hazardous drug list D. Use of closed-system transfer devices (CSTDs)
[expand]Answer: D. Use of closed-system transfer devices (CSTDs)
Explanation: ASCO states that a certified standard is needed to gauge the effectiveness of commercially available CSTDs — more research is needed in this area. For negative pressure rooms, double-gloving, and institutional HD lists — ASCO endorses USP <800> standards, which require all three.
[/expand]Which is most correct about the standards in USP <800>?
A. "Must" indicates a requirement and "should" indicates a recommendation B. Only applies in hospital settings C. Outlines requirements for medical surveillance for healthcare workers handling HDs D. Recommendations mirror those in USP <797>
[expand]Answer: A. "Must" indicates a requirement and "should" indicates a recommendation
Explanation: USP <800> consistently uses "must" for requirements and "should" for recommendations. USP <800> applies beyond hospitals to all settings where HDs are handled. Surveillance for HD-exposed healthcare workers is a recommendation ("should"), not a requirement. USP <800> standards have been removed from the updated USP <797> chapter.
[/expand]According to USP <800>, which is a requirement for nursing administration of HDs?
A. Use of a closed-system transfer device when the dosage form allows B. A dedicated mortar and pestle for crushing HD oral dosage forms C. N-95 respirator D. Specialized IV tubing to allow for priming with HD solution
[expand]Answer: A. Use of a closed-system transfer device when the dosage form allows
Explanation: USP <800> requires the use of CSTDs during nursing administration of HDs when the dosage form allows (injectable HDs). CSTDs mechanically prohibit the transfer of environmental contaminants and prevent escape of HD or vapor from the system.
[/expand]Under 340B, which of the following is considered a "covered entity"? (Select all that apply)
A. Rural hospitals B. Cancer research centers C. Children's hospitals D. Teaching hospitals
[expand]Answer: A, C, and D — Rural hospitals, Children's hospitals, and Teaching hospitals
Explanation: The 340B Drug Pricing Program covered entities include rural hospitals meeting disproportionate share criteria, children's hospitals, and teaching hospitals meeting the statutory requirements. Cancer research centers are NOT automatically 340B covered entities — they must meet specific criteria as free-standing cancer hospitals.
[/expand]Biosimilars adoption barriers — which is correct regarding the ASCO statement?
A. ASCO mandates post-marketing safety studies for each biosimilar B. The most important concern is that interchangeability mandates pharmacy substitution decisions C. Incentives and rebate contracts with reference products are also barriers
[expand]Answer: B. The most important concern is that interchangeability mandates pharmacy substitution decisions
Explanation: According to ASCO's position on biosimilar adoption barriers, the most important concern is that interchangeability designation allows pharmacists to substitute a biosimilar for the reference product without prescriber involvement. Incentives and rebate contracts are also acknowledged barriers. ASCO does NOT mandate post-marketing safety studies for each individual biosimilar.
[/expand]Which of the following is NOT correct regarding cytotoxic drug handling?
A. Negative pressure room is a must B. When preparing, you must wear two pairs of chemotherapy-resistant gloves C. Surgical masks are enough when you handle spills D. Administration of IV drugs requires CSTD
[expand]Answer: C. Surgical masks are enough when you handle spills
Explanation: Surgical masks are NOT adequate for HD spill management. When attending to a chemotherapy spill, an N-95 respirator is required to protect against airborne HD vapors and particles. Negative pressure room is a USP <800> requirement for compounding HD CSPs. Double gloves are required for all HD handling including preparation. CSTDs are required for IV HD administration when the dosage form allows.
[/expand]Which of the following is a Group 1 NIOSH list drug?
A. Fluconazole B. Tacrolimus C. Azathioprine D. Pertuzumab
[expand]Answer: D. Pertuzumab
Explanation: NIOSH Group 1 consists of antineoplastic drugs — the highest hazard category. Pertuzumab is an anti-HER2 monoclonal antibody used as an antineoplastic agent and belongs to Group 1. Tacrolimus and azathioprine are NIOSH Group 2 drugs (non-antineoplastic with reproductive risk). Fluconazole is not a NIOSH hazardous drug.
[/expand]Which of the following cabinets can be used in preparing chemotherapy drugs?
A. Laminar Airflow Workbench (LAFW) B. Containment Aseptic Isolator C. BSC Class II Type A1 D. Containment Aseptic Containment Isolator (CACI)
[expand]Answer: D. Containment Aseptic Containment Isolator (CACI)
Explanation: Per USP <800>, HD CSPs must be prepared in a containment primary engineering control (C-PEC) such as an externally vented Class II BSC or a Containment Aseptic Containment Isolator (CACI). A LAFW is never appropriate for compounding HDs. A Containment Aseptic Isolator (CAI) is used for non-hazardous sterile compounding. A BSC Class II Type A1 recirculates air and does not provide adequate HD containment — only externally vented types are acceptable.
[/expand]Which of the following does NOT follow RCRA requirements and is not considered hazardous waste? (Choose 2)
A. Nicotine in gums B. Expired oxaliplatin vial C. Nicotine in vapes D. IND drug after study end E. Warfarin
[expand]Answer: A. Nicotine in gums and C. Nicotine in vapes
Explanation: The Hazardous Waste Pharmaceuticals amendment to RCRA allows FDA-approved nicotine replacement therapies — including patches, gum, and other nicotine replacement products — to be discarded as non-hazardous waste. Expired oxaliplatin vials are U-listed hazardous waste (antineoplastic). IND drugs after a study ends must be disposed of per hazardous waste regulations if they qualify as HDs. Warfarin remains a U-listed hazardous waste drug.
[/expand]Which of the following is under Domain 3 of ASCO/ONS safety standards?
A. BLS-certified person during administration B. Verbal and written patient information C. Follow-up of cumulative chemotherapy dose toxicity D. Out-of-standard regimens should be signed by another practitioner
[expand]Answer: D. Out-of-standard regimens should be signed by another practitioner
Explanation: Domain 3 of the ASCO/ONS safety standards covers prescribing and ordering safety, which includes: no verbal orders for chemotherapy accepted (except to hold or stop), requirements for intrathecal chemotherapy preparation policies, and the requirement that non-standard regimens be approved or co-signed by a second qualified practitioner. Cumulative dose tracking falls under Domain 4.
[/expand]Which characteristic of clinical pathways is being advocated by national professional oncology societies?
A. Oncology pathways should include issues beyond drug treatment regimens such as survivorship and end-of-life care B. Pathway compliance should approximate 100% with well-written pathways C. Commercial entities such as drug wholesalers should not draft or support oncology clinical pathways D. Diversity and variation in application of commercially available pathways supports physician autonomy
[expand]Answer: A. Oncology pathways should include issues beyond drug treatment regimens such as survivorship and end-of-life care
Explanation: ASCO has advocated that clinical pathways provide guidance beyond drug prescribing, including recommendations for end-of-life care, survivorship, surgical intervention, and radiation therapy. Pathway compliance of 70–80% is considered best-case scenario — not 100%. Most commercially available pathways ARE written by corporate entities. ASCO is advocating for more uniform (not divergent) pathway development.
[/expand]Which characteristic is most reflective of a drug dispensed by a specialty pharmacy?
A. Drugs with multiple CYP450-mediated drug interactions B. Agents with a high likelihood of profound myelosuppression C. Any oral agent approved for the treatment of cancer D. Agents with specific handling, storage, and delivery requirements
[expand] Answer: D. Agents with specific handling, storage, and delivery requirementsExplanation: Specialty pharmacies provide intensive patient education about proper use, toxicity, and any unique handling/storage issues. They coordinate home delivery and manage logistical issues. Drug designation as specialty is NOT predicated on specific toxicities, drug interactions, or being an oral anticancer agent alone. Many oral anticancer agents (hormonal therapy for breast/prostate cancer, older cytotoxics like cyclophosphamide) are not specialty medications.
[/expand]4. How many half-lives of a drug does it take before a drug has either achieved over 90% of the steady-state concentrations (Css) – (Note: assume first-order kinetics, no loading dose was given, and the patient is taking the drug at the appropriately prescribed frequency of administration)?
- A 1 – 2 (3%)
- B 2 – 3 (7%)
- C 4 – 5 (88%)
- D 6 – 8 (3%)
<
p class=”ds-markdown-paragraph”>[expand] Answer (C)
Remember, after 1 half-life, 50% of the first dose remains. After 2 half-lives, 75% of the two doses remain. After 3 half-lives, 87.5% of the three doses remain, and after 4 half-lives, 93.75% of the doses remain, which is very close to the steady-state concentration (Css) – assuming that the patient is taking a medication that follows 1st order kinetics (which is most medications). No loading dose was given, and the patient takes the medications at the appropriate frequency.
[/expand][/su_note]5. Which of the following clearance pathways in the body do most medications rely upon?
- A. Liver metabolism (53%)
- B. Renal elimination (46%)
- C. Biliary elimination (1%)
- D. Sensible loss through exhalation (1%)
- The majority of clearance pathways for medications is in the liver via various metabolic pathways such as the cytochrome P450 (CYP450) enzyme system in phase I metabolism and conjugate pathways associated with phase II metabolism. The purpose of the microsomal CYP450 enzymes is to give/add a functional group to the drug molecule in preparation for phase II metabolism and/or elimination. Those functional groups are: -COOH, -OH, -NH2, -SH. It is also important to note that not all metabolic reactions by the CYP450 enzymes result in the inactivation of drugs; some actually metabolize the drug molecule into an active form. A good example of this is a medication that is given as a prodrug formulation and, once in the body, it gets converted into an active form. Such a situation is seen with the antiplatelet medication, clopidogrel (Plavix).
- Renal is second, and then biliary. Sensible loss through exhalation is only used by a small fraction of volatile medications, not commonly used in medical practice for most situations.
6. Which of the following best describes a medication that is most likely to have a low volume of distribution (Vd)?
- A. A highly hydrophilic drug (67%)
- B. A highly lipophilic drug (21%)
- C. A drug with very low water solubility (10%)
- D. A drug that has a molecular weight of less than 750 daltons (2%)
Hydrophilic or “water-loving” drugs are less likely to cross through cell membranes and get into tissue. As such, they tend to have lower volumes of distribution (Vd). Choices b and c are the opposite and would have larger volumes of distribution. Choice D is non-specific and cannot be used to determine this (i.e., it is a distractor that sounds good).
[/expand]7. A patient has been taking Drug A for three months with a good response. This patient is then started on Drug B, and now the patient is reporting that the response to Drug A is less. Which of the following best describes this drug interaction? (Select all that apply)
- A. Drug B is causing an irreversible drug interaction at the same receptor binding site as Drug A (10%)
- B. Drug B has a greater degree of protein binding than Drug A (6%)
- C. Drug B is competing with Drug A for the same receptor binding site (47%)
- D. The use of Drug B requires a larger dose of Drug A to achieve the same efficacy seen prior to starting Drug B (37%)
- The third and last answer choices are correct.
- This graph reflects a shift to the right in the dose-response curve that is classically seen in patients experiencing a competitive drug-drug interaction where both Drug A and Drug B are trying to compete for the same receptor binding site.
- When a competitive drug interaction is occurring between two drugs at the same receptor binding site, increasing the dose of Drug A will overcome the competition being created by the presence of Drug B.
- If Drug B was causing an irreversible drug interaction with Drug A, there would be a reduction in the maximal pharmacokinetic response that could be achieved with Drug A, even if the dose of Drug A was to be increased. This pertains to the first answer choice.
- A drug with a greater degree of protein binding would mean there is less "free" or "unbound" drug, but would not be reflective by this change in the dose-response curve of Drug A, and the second answer choice is only serving as a distractor.
- A shift to the right in the dose-response curve is classically seen with a drug-drug interaction that is competitive in nature and is typically reversible.
- A classic example of competitive interaction for the same receptor is between naloxone and morphine. Naloxone (Narcan) is structurally very similar to morphine but does not function as an agonist to the receptor, and when administered, it will compete with morphine for the binding site, thereby reducing the activity of morphine. This effect can be overcome by giving more morphine or by waiting for naloxone to be eliminated from the body.
- A shift to the right in a drug’s dose-response curve can also be seen with the development of tolerance where now a greater dose is needed in order to achieve the same pharmacologic response. This is classically seen with patients taking chronic opioid analgesic medications for pain control
25. Which of the following dosing administration techniques can facilitate the time to achieve steady-state concentrations (Css)?
- A. Loading dose (93%)
- B. Decrease in dosing frequency of administration (3%)
- C. Reducing the frequency of administration but not the dosage of the medication (3%)
- D. Increasing the renal or biliary elimination (1%)
Answer A is the only option that will contribute to the achievement of steady-state concentrations (Css). The formula for determining the loading dose (LD) needed is: LD = Co x Vd (Note: the Co - desired initial blood concentration of the drug. Vd - volume of distribution of the drug). The other options will all decrease the amount of drug being administered. Giving loading doses is very common in clinical practice, especially when achieving Css allows for a desired benefit in an acute or emergent situation. The below diagrams reflect the differences in achieving the Css for a drug. Giving a LD may be needed in situations such as: seizures, cardiac arrhythmias, antiplatelet therapy during cardiac catheterization.
[/expand]